

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("0688802").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/02/22 06:27
L2	2	("6888027").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/02/22 06:27
L3	2	("6087367").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/02/22 06:27
L4	2	("9816503").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/02/22 06:27
L5	2	("5534654").PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/02/22 06:27
L6	1209	HDAC	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 06:28
L7	2232	histone adj deacetylase	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 06:28
L8	2603	I6 or I7	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 06:29
L9	13476	hydroxam\$	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 06:29
L10	460	I7 and I9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 06:29
L11	302	I7 same I9	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 06:31

EAST Search History

L12	10	"6541661"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 07:03
L13	10	"9816503"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 07:49
L14	6	"5534654"	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 09:10
L15	266	562/623.ccls.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 09:10
L16	11	l10 and l15	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	ON	2007/02/22 09:11

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	Feb 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	Feb 15	RUSSIAPAT enhanced with pre-1994 records
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:20:08 ON 20 FEB 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:20:20 ON 20 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.45

0.66

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:20:28 ON 20 FEB 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'REGISTRY' AT 10:38:00 ON 20 FEB 2007

FILE 'REGISTRY' ENTERED AT 10:38:00 ON 20 FEB 2007

COPYRIGHT (C) 2007 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY


SESSION

0.45

0.66

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10811332\10811332 elected specie.str



chain nodes :

7 8 9 10 11 12 13 14 15 16 23 24

ring nodes :

1 2 3 4 5 6 17 18 19 20 21 22

chain bonds :

2-13 6-8 7-10 7-8 9-10 10-11 11-12 13-14 13-15 13-16 14-17 20-23 23-24

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

exact/norm bonds :

2-13 9-10 10-11 13-14 13-15 13-16 14-17 20-23 23-24

exact bonds :

6-8 7-10 7-8 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom


19:Atom 20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l1 exact full

FULL SEARCH INITIATED 10:39:28 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 45 TO ITERATE

100.0% PROCESSED 45 ITERATIONS

2 ANSWERS

SEARCH TIME: 00.00.01

L2 2 SEA EXA FUL L1

=> \\d scan

8598666 D

47 SCAN

L3 0 \\D SCAN


(D(W)SCAN)

=> d scan l2

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Propenamide, N-hydroxy-3-[3-[[4-methoxyphenyl]amino]sulfonyl]phenyl]-
(9CI)

MF C16 H16 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Propenamide, N-hydroxy-3-[3-[[4-methoxyphenyl]amino]sulfonyl]phenyl]-,
(2E)- (9CI)

MF C16 H16 N2 O5 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
69.50	69.71

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:40:19 ON 20 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Feb 2007 VOL 146 ISS 9

FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> 12

L4 2 L2

=> d 14 1-2 ti fbib abs

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

TI Novel sulfonamide derivatives as inhibitors of histone deacetylase

AN 2005:842556 CAPLUS

DN 143:359422

TI Novel sulfonamide derivatives as inhibitors of histone deacetylase

AU Finn, Paul W.; Bandara, Morwena; Butcher, Chris; Finn, Angela; Hollinshead, Ruth; Khan, Nagma; Law, Norman; Murthy, Sreenivasa; Romero, Rosario; Watkins, Clare; Andrianov, Victor; Bokaldere, Rasma M.; Dikovska, Klara; Gailite, Vija; Loza, Einars; Piskunova, Irina; Starchenkov, Igor; Vorona, Maxim; Kalvinsh, Ivars

CS TopoTarget UK Ltd., Abingdon, OX14 4RY, UK

SO Helvetica Chimica Acta (2005), 88(7), 1630-1657

CODEN: HCACAV; ISSN: 0018-019X
 PB Verlag Helvetica Chimica Acta
 DT Journal
 LA English
 OS CASREACT 143:359422
 AB Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivs. were synthesized and evaluated for their ability to inhibit human HDAC. Compds. were identified which are potent enzyme inhibitors, with IC50 values in the low nanomolar range against enzyme obtained from HeLa cell exts., and with antiproliferative effects in cell culture. Extensive characterization of the structure-activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central Ph ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compds., mll.1, also designated PXD101, has entered clin. trials for solid tumors and haematol. malignancies.

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of aryl-substituted N-hydroxy amides with sulfonamide linkages as HDAC inhibitors for treatment of proliferative conditions
 AN 2002:293604 CAPLUS
 DN 136:325325
 TI Preparation of aryl-substituted N-hydroxy amides with sulfonamide linkages as HDAC inhibitors for treatment of proliferative conditions
 IN Watkins, Clare J.; Romero-Martin, Maria-Rosario; Moore, Kathryn G.; Ritchie, James; Finn, Paul W.; Kalvinsh, Ivars; Loza, Einars; Dikovska, Klara; Gailite, Vija; Vorona, Maxim; Piskunova, Irina; Starchenkov, Igor; Adrianov, Victor; Harris, C. John; Duffy, James E. S.
 PA Prolifix Limited, UK
 SO PCT Int. Appl., 267 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030879	A2	20020418	WO 2001-GB4326	20010927
	WO 2002030879	A3	20020627		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
				GB 2000-23986	A 20000929
				US 2001-297784P	P 20010614
				US 2001-308136P	P 20010730
	CA 2423744	A1	20020418	CA 2001-2423744	20010927
				GB 2000-23986	A 20000929
				US 2001-297784P	P 20010614
				US 2001-308136P	P 20010730
				WO 2001-GB4326	W 20010927
	AU 200190131	A	20020422	AU 2001-90131	20010927
				GB 2000-23986	A 20000929
				US 2001-297784P	P 20010614
				US 2001-308136P	P 20010730

EP 1328510	A2	20030723	WO 2001-GB4326	W	20010927
			EP 2001-970011		20010927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			WO 2001-GB4326	W	20010927
JP 2004511462	T	20040415	JP 2002-534267		20010927
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			WO 2001-GB4326	W	20010927
NZ 525439	A	20041126	NZ 2001-525439		20010927
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			WO 2001-GB4326	W	20010927
NZ 535065	A	20060526	NZ 2001-535065		20010927
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			NZ 2001-525439	A1	20010927
US 2004077726	A1	20040422	US 2003-381790		20030820
US 6888027	B2	20050503			
			GB 2000-23986	A	20000929
			WO 2001-GB4326	W	20010927
US 2005107445	A1	20050519	US 2004-811332		20040329
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			WO 2001-GB4326	W	20010927
			US 2003-381790	A3	20030820
US 2005085515	A1	20050421	US 2004-953106		20040930
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			WO 2001-GB4326	W	20010927
			US 2003-381790	A1	20030820
US 2007004806	A1	20070104	US 2006-516620		20060907
			GB 2000-23986	A	20000929
			US 2001-297784P	P	20010614
			US 2001-308136P	P	20010730
			WO 2001-GB4326	W	20010927
			US 2003-381790	A1	20030820
			US 2004-953106	A1	20040930

OS MARPAT 136:325325

AB The title compds. A_{Q1}JQ₂CONHOH (I) [wherein A = aryl group; Q₁ = covalent bond or aryl leader group having a backbone of at least 2 C atoms; J = SO₂NR₁ or NR₁SO₂; R₁ = sulfonamido substituent; Q₂ = acid leader group; with the proviso that if J is SO₂NR₁, then Q₁ is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemical protected forms, and prodrugs thereof] were prepared as histone deacetylase (HDAC) inhibitors for treatment of proliferative conditions, such as cancer and psoriasis. For example, 3-(3-sulfonylphenyl)acrylic acid Me ester (preparation given) was coupled with 1-aminonaphthalene to give the sulfonamide (51%). Deesterification (79%), followed by conversion to the acid chloride (99%) and treatment with HONH₂•HCl in the presence of NaHCO₃ in THF, afforded N-hydroxy-3-[3-(naphthalen-1-ylsulfamoyl)phenyl]acrylamide (PX117228) in 24% yield. The latter inhibited HDAC from crude human cervical adenocarcinoma (HeLa) extract with IC₅₀ of 7 nM and inhibited cell proliferation against the HeLa cell line using cell proliferation reagent WST-1 with IC₅₀ of 0.8 nM.

Structure-activity relationship studies showed superior activity for I when (1) a reverse sulfonamide, i.e. NHSO_2 , was employed as J, (2) a covalent bond or aryl leader having a backbone of at least 2C atoms was used as Q1, and/or (3) a phenylene-meta-alkylene linkage was employed as Q2.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.77	81.48

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.56	-1.56

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:48:17 ON 20 FEB 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:23:43 ON 20 FEB 2007
FILE 'CAPLUS' ENTERED AT 11:23:43 ON 20 FEB 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.77	81.48

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.56	-1.56

CA SUBSCRIBER PRICE

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
11.77	81.48

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-1.56	-1.56

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 11:23:51 ON 20 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary files\10811332\10811332 first stab.str



chain nodes :

7 8 9 10 11 12 13 14 15

ring nodes :

1 2 3 4 5 6

chain bonds :

6-7 7-9 8-9 9-10 10-11 12-14 12-13 13-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

8-9 9-10 12-14 12-13 13-15

exact bonds :

6-7 7-9 10-11

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom

L5 STRUCTURE UPLOADED

=> d 125


L25 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d 15

L5 HAS NO ANSWERS

L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> search l5 sss sam

SAMPLE SEARCH INITIATED 11:24:53 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1227 TO ITERATE

100.0% PROCESSED 1227 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 22439 TO 26641

PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> search l5 sss full

FULL SEARCH INITIATED 11:25:05 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 24958 TO ITERATE

100.0% PROCESSED 24958 ITERATIONS

29 ANSWERS

SEARCH TIME: 00.00.01


L7 29 SEA SSS FUL L5

=> d scan

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 1,2-Benzenedicarboxamide, N-[8-(dimethylamino)-1-naphthalenyl]-N'-hydroxy-
(9CI)


MF C20 H19 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):29

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(2-nitro-3-pyridinyl)- (9CI)
 MF C13 H10 N4 O5



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(2-mercaptophenyl)- (9CI)
 MF C14 H12 N2 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(2-hydroxyphenyl)- (9CI)

MF C14 H12 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(2-hydroxy-4-nitrophenyl)- (9CI)
MF C14 H11 N3 O6




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)- (9CI)
MF C22 H26 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1,4-Benzenedicarboxamide, N-(3,4-dimethylphenyl)-N'-hydroxy- (9CI)
MF C16 H16 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-(4-butylphenyl)-N'-hydroxy- (9CI)
 MF C18 H20 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(4-propylphenyl)- (9CI)
 MF C17 H18 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(3-methylphenyl)- (9CI)
 MF C15 H14 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-(2,3-dihydro-1H-inden-1-yl)-N'-hydroxy- (9CI)
 MF C17 H16 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-cyclohexyl-N'-hydroxy- (9CI)
 MF C14 H18 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benamide, 3-[3-(hydroxyamino)-3-oxo-1-propenyl]-N-phenyl- (9CI)
 MF C16 H14 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-phenyl- (9CI)
 MF C14 H12 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, 2-chloro-N1-[4-chloro-3-(2-pyridinyl)phenyl]-N4-hydroxy- (9CI)
 MF C19 H13 Cl2 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-(2-aminophenyl)-N'-hydroxy- (9CI)
 MF C14 H13 N3 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-(3-acetylphenyl)-N'-hydroxy- (9CI)
 MF C16 H14 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(3-hydroxy-2-naphthalenyl)- (9CI)
 MF C18 H14 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(2-hydroxy-3-methylphenyl)- (9CI)
 MF C15 H14 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,2-Benzenedicarboxamide, N-hydroxy-N'-(2-hydroxy-5-methylphenyl)- (9CI)
 MF C15 H14 N2 O4




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(4-methylphenyl)- (9CI)
 MF C18 H22 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-[4-(1,1-dimethylethyl)phenyl]-N'-hydroxy- (9CI)
 MF C18 H20 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-[4-(1-methylethyl)phenyl]- (9CI)
 MF C17 H18 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-(4-ethylphenyl)-N'-hydroxy- (9CI)
 MF C16 H16 N2 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-(4-methylphenyl)- (9CI)
 MF C15 H14 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-cyclopropyl-N'-hydroxy- (9CI)
 MF C11 H12 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzenehexanamide, N, ϵ -dihydroxy-4-[(phenylamino)carbonyl]-,
 (eR)- (9CI)
 MF C19 H22 N2 O4

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzenepropanamide, 4-[[(2-aminophenyl)amino]carbonyl]-N-hydroxy- (9CI)
 MF C16 H17 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L7 29 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxamide, N-hydroxy-N'-phenyl- (9CI)
 MF C14 H12 N2 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> save temp l7 rawhits/a
ANSWER SET L7 HAS BEEN SAVED AS 'RAWHITS/A'

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.45	254.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.56

FILE 'CAPLUS' ENTERED AT 11:26:30 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l7

L8 12 L7

=> save temp l8 1ststabhits/a

1STSTABHITS/A IS NOT A VALID SAVED NAME

Enter the name you wish to use for the saved query, answer set, or L-number list. The name must:

1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile, structure, or screen set), /A for an answer set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).

ENTER NAME OR (END):ends/a

ANSWER SET L8 HAS BEEN SAVED AS 'ENDS/A'

=> save temp l8 onestabhits/a

ANSWER SET L8 HAS BEEN SAVED AS 'ONESTABHITS/A'

=> d l8 1-12 ti

L8 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of arylpyridines as inhibitors of hedgehog signalling.

L8 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Compounds for inhibiting copper-containing amine oxidases and their use in inflammatory disease

L8 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase (HDAC) inhibitors.

L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.

L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of thiophenedicarboxamides and related compounds as histone deacetylase (HDAC) inhibitors.

L8 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

L8 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of alkanolic acid derivatives as novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof

L8 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of hydroxamic acids and their use as antitumor agents

L8 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of arylhydroxamates and related compounds as potent inducers of terminal differentiation.

L8 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of alkanedicarboxylic acid amides as novel potent inducers of terminal differentiation of neoplastic cell

L8 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Nucleophilic reactions of N-hydroxy-, methoxy-, 2,3-epoxypropoxy-phthalimides


L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Alkanedioic acid derivatives, novel potent inducers of terminal differentiation and methods of use thereof

=> d l8 1-12 ti fbib abs it

L8 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of arylpyridines as inhibitors of hedgehog signalling.
 AN 2006:238237 CAPLUS
 DN 144:311912
 TI Preparation of arylpyridines as inhibitors of hedgehog signalling.
 IN Gunzner, Janet; Sutherlin, Daniel; Stanley, Mark; Bao, Liang; Castanedo, Georgette; Lalonde, Rebecca; Wang, Shumei; Reynolds, Mark; Savage, Scott; Malesky, Kimberly; Dina, Michael
 PA Genentech, Inc., USA; Curis Incorporation
 SO PCT Int. Appl., 256 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 2006028958	A2	20060316	WO 2005-US31284	20050902
	WO 2006028958	A3	20060413		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006063779	A1	20060323	US 2004-607367P	P 20040902
				US 2005-217663	20050902
				US 2004-607367P	P 20040902
OS	MARPAT 144:311912				
GI					



- AB Title compds. [I; A = carbocyclyl, heterocyclyl; X = alkylene, NR₄CO, NR₄CS, NR₄SO₂, NR₄PO(OH), etc.; R₁ = (substituted) alkyl, carbocyclyl, heterocyclyl; R₂ = halo, OH, (substituted) alkyl, acyl, alkoxy; R₃ = halo, OH, CO₂H, (substituted) alkyl, acyl, alkoxy, alkoxy carbonyl, carbamoyl, alkylthio, sulfinyl, sulfonyl, carbocyclyl, heterocyclyl; R₄ = H, alkyl; m, n = 0-3], were prepared for treatment of cancer (no data). Thus, N-[4-chloro-3-(pyridin-2-yl)phenyl]-6-chloro-3-carboxamide and 2-morpholinoethylamine were heated in BuOH in a sealed tube to give 6-(2-morpholinoethylamino)-N-[4-chloro-3-(pyridin-2-yl)phenyl]-6-chloro-3-carboxamide.
- IT Pancreas, neoplasm
(adenocarcinoma; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Skin, neoplasm
(basal cell carcinoma, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Carcinoma
(basal cell, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Mammary gland, neoplasm
(carcinoma, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Carcinoma
(mammary, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Brain, neoplasm
(medulloblastoma, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Carcinoma
(pancreatic adenocarcinoma; preparation of arylpyridines as inhibitors of hedgehog signaling)
- IT Antitumor agents
Drug delivery systems
Human

(preparation of arylpyridines as inhibitors of hedgehog signaling)

IT Hedgehog protein
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of arylpyridines as inhibitors of hedgehog signaling)

IT Carcinoma
(pulmonary small-cell, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)

IT Sarcoma
(rhabdomyosarcoma, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)

IT Lung, neoplasm
(small-cell carcinoma, treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)

IT Biliary tract, neoplasm
Esophagus, neoplasm
Neoplasm
Stomach, neoplasm
(treatment; preparation of arylpyridines as inhibitors of hedgehog signaling)

IT 879087-70-4P 879087-90-8P 879087-98-6P 879088-09-2P 879088-20-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of arylpyridines as inhibitors of hedgehog signaling)

IT 879085-20-8P 879085-21-9P 879085-22-0P 879085-23-1P 879085-24-2P
879085-25-3P 879085-26-4P 879085-27-5P 879085-28-6P 879085-29-7P
879085-30-0P 879085-31-1P 879085-32-2P 879085-33-3P 879085-34-4P
879085-35-5P 879085-36-6P 879085-37-7P 879085-38-8P 879085-39-9P
879085-40-2P 879085-41-3P 879085-42-4P 879085-43-5P 879085-44-6P
879085-45-7P 879085-46-8P 879085-47-9P 879085-48-0P 879085-49-1P
879085-50-4P 879085-51-5P 879085-52-6P 879085-53-7P 879085-54-8P
879085-55-9P 879085-56-0P 879085-57-1P 879085-58-2P 879085-59-3P
879085-60-6P 879085-61-7P 879085-62-8P 879085-63-9P 879085-64-0P
879085-65-1P 879085-66-2P 879085-67-3P 879085-68-4P 879085-69-5P
879085-70-8P 879085-71-9P 879085-72-0P 879085-73-1P 879085-74-2P
879085-75-3P 879085-76-4P 879085-77-5P 879085-78-6P 879085-79-7P
879085-80-0P 879085-81-1P 879085-82-2P 879085-83-3P 879085-84-4P
879085-85-5P 879085-86-6P 879085-87-7P 879085-88-8P 879085-89-9P
879085-90-2P 879085-91-3P 879085-92-4P 879085-93-5P 879085-94-6P
879085-95-7P 879085-96-8P 879085-97-9P 879085-98-0P 879085-99-1P
879086-00-7P 879086-01-8P 879086-02-9P 879086-03-0P 879086-04-1P
879086-05-2P 879086-06-3P 879086-07-4P 879086-08-5P 879086-09-6P
879086-10-9P 879086-11-0P 879086-12-1P 879086-13-2P 879086-14-3P
879086-15-4P 879086-16-5P 879086-17-6P 879086-18-7P
879086-19-8P 879086-20-1P 879086-21-2P 879086-22-3P 879086-23-4P
879086-24-5P 879086-25-6P 879086-26-7P 879086-27-8P 879086-28-9P
879086-29-0P 879086-30-3P 879086-31-4P 879086-32-5P 879086-34-7P
879086-35-8P 879086-36-9P 879086-37-0P 879086-38-1P 879086-39-2P
879086-40-5P 879086-41-6P 879086-42-7P 879086-43-8P 879086-44-9P
879086-45-0P 879086-46-1P 879086-47-2P 879086-48-3P 879086-49-4P
879086-50-7P 879086-51-8P 879086-52-9P 879086-53-0P 879086-54-1P
879086-55-2P 879086-56-3P 879086-57-4P 879086-58-5P 879086-59-6P
879086-60-9P 879086-61-0P 879086-62-1P 879086-63-2P 879086-64-3P
879086-65-4P 879086-66-5P 879086-67-6P 879086-68-7P 879086-69-8P
879086-70-1P 879086-71-2P 879086-72-3P 879086-73-4P 879086-74-5P
879086-75-6P 879086-76-7P 879086-77-8P 879086-78-9P 879086-79-0P
879086-80-3P 879086-81-4P 879086-82-5P 879086-83-6P 879086-84-7P
879086-85-8P 879086-86-9P 879086-87-0P 879086-88-1P 879086-89-2P
879086-90-5P 879086-91-6P 879086-92-7P 879086-93-8P 879086-95-0P
879086-96-1P 879086-97-2P 879086-98-3P 879086-99-4P 879087-00-0P
879087-01-1P 879087-02-2P 879087-03-3P 879087-04-4P 879087-05-5P
879087-06-6P 879087-07-7P 879087-08-8P 879087-09-9P 879087-10-2P
879087-11-3P 879087-12-4P 879087-13-5P 879087-14-6P 879087-15-7P

879087-16-8P	879087-17-9P	879087-18-0P	879087-19-1P	879087-20-4P
879087-21-5P	879087-22-6P	879087-23-7P	879087-24-8P	879087-25-9P
879087-26-0P	879087-27-1P	879087-28-2P	879087-29-3P	879087-30-6P
879087-31-7P	879087-32-8P	879087-33-9P	879087-34-0P	879087-35-1P
879087-36-2P	879087-37-3P	879087-38-4P	879087-39-5P	879087-40-8P
879087-41-9P	879087-42-0P	879087-43-1P	879087-44-2P	879087-45-3P
879087-46-4P	879087-47-5P	879087-48-6P	879087-49-7P	879087-50-0P
879087-51-1P	879087-52-2P	879087-53-3P	879087-54-4P	879087-55-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpyridines as inhibitors of hedgehog signaling)

IT	879087-56-6P	879087-57-7P	879087-58-8P	879087-59-9P	879087-60-2P
	879087-61-3P	879087-62-4P	879087-63-5P	879087-64-6P	879087-65-7P
	879087-66-8P	879087-67-9P	879087-68-0P	879087-69-1P	879087-71-5P
	879087-72-6P	879087-73-7P	879087-74-8P	879087-75-9P	879087-76-0P
	879087-77-1P	879087-78-2P	879087-79-3P	879087-80-6P	879087-81-7P
	879087-82-8P	879087-83-9P	879087-84-0P	879087-85-1P	879087-86-2P
	879087-87-3P	879087-88-4P	879087-89-5P	879087-91-9P	879087-92-0P
	879087-93-1P	879087-94-2P	879087-95-3P	879087-96-4P	879087-97-5P
	879087-99-7P	879088-00-3P	879088-01-4P	879088-02-5P	879088-03-6P
	879088-04-7P	879088-05-8P	879088-06-9P	879088-07-0P	879088-08-1P
	879088-10-5P	879088-11-6P	879088-12-7P	879088-13-8P	879088-14-9P
	879088-15-0P	879088-16-1P	879088-17-2P	879088-18-3P	879088-19-4P
	879088-21-8P	879088-22-9P	879088-23-0P	879088-24-1P	879088-25-2P
	879088-26-3P	879088-27-4P	879088-28-5P	879088-29-6P	879088-30-9P
	879088-31-0P	879088-32-1P	879088-33-2P	879088-34-3P	879088-35-4P
	879088-36-5P	879088-37-6P	879088-38-7P	879088-39-8P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of arylpyridines as inhibitors of hedgehog signaling)

IT 51-45-6, Histamine, reactions 60-24-2, 2-Mercaptoethanol 61-82-5, 3-Amino-1,2,4-triazole 62-23-7, 4-Nitrobenzoic acid 62-53-3, Aniline, reactions 67-51-6, 3,5-Dimethylpyrazole 75-03-6, Iodoethane 75-04-7, Ethylamine, reactions 75-08-1, Ethanethiol 75-31-0, Isopropylamine, reactions 75-33-2, 2-Propanethiol 75-64-9, tert-Butylamine, reactions 78-77-3, 1-Bromo-2-methylpropane 78-81-9, Isobutylamine 79-14-1, Glycolic acid, reactions 79-19-6, Thiosemicarbazide 85-41-6, Isoindoline-1,3-dione 95-72-7, 2-Chloro-1,4-dimethylbenzene 96-50-4, 2-Aminothiazole 98-88-4, Benzoyl chloride 100-09-4, 4-Methoxybenzoic acid 100-46-9, Benzylamine, reactions 103-67-3, N-Methyl-1-phenylmethanamine 103-76-4, N-(2-Hydroxyethyl)piperazine 104-63-2, 2-(Benzylamino)ethanol 104-78-9 106-93-4, 1,2-Dibromoethane 107-03-9, 1-Propanethiol 107-10-8, Propylamine, reactions 108-49-6, 2,6-Dimethylpiperazine 108-91-8, Cyclohexanamine, reactions 109-01-3, N-Methylpiperazine 109-07-9, 2-Methylpiperazine 109-85-3, 2-Methoxyethanamine 110-85-0, Piperazine, reactions 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 118-91-2, 2-Chlorobenzoic acid 123-00-2, N-(3-Aminopropyl)morpholine 123-75-1, Pyrrolidine, reactions 123-90-0, Thiomorpholine 138-41-0, 4-Carboxybenzenesulfonamide 141-43-5, Ethanolamine, reactions 141-91-3, 2,6-Dimethylmorpholine 142-25-6, N,N,N'-Trimethylethylenediamine 156-87-6, Propanolamine 288-13-1, 1H-Pyrazole 288-36-8, 1H-1,2,3-Triazole 288-88-0, 1H-1,2,4-Triazole 330-17-6, 4-(Trifluoromethylthio)benzoic acid 353-83-3, 2,2,2-Trifluoroethyl iodide 393-55-5, 2-Fluoronicotinic acid 462-08-8, 3-Aminopyridine 497-25-6, 2-Oxazolidone 504-29-0, 2-Aminopyridine 504-78-9, Thiazolidine 505-66-8 506-59-2, Dimethylamine hydrochloride 513-38-2, 1-Iodo-2-methylpropane 584-13-4, 4-Amino-1,2,4-triazole 586-30-1, 3-Hydroxy-4-methylbenzoic acid 593-51-1, Methylamine hydrochloride 593-56-6 594-44-5, Ethanesulfonyl chloride 598-21-0, Bromoacetyl bromide 616-45-5, 2-Pyrrolidinone 618-36-0,

1-Phenylethanamine 619-44-3, Methyl 4-iodobenzoate 619-65-8,
 4-Cyanobenzoic acid 621-83-0, N-Benzylthiourea 660-68-4, Diethylamine
 hydrochloride 683-57-8, 2-Bromoacetamide 704-45-0,
 2-Methoxy-4-methylbenzoic acid 753-90-2, 2,2,2-Trifluoroethylamine
 822-36-6, 4-Methylimidazole 922-67-8, Methyl propiolate 1068-47-9,
 1-Mercapto-2-propanol 1122-71-0, (6-Methylpyridin-2-yl)methanol
 1129-28-8, Methyl 3-(bromomethyl)benzoate 1192-21-8,
 5-Amino-1-methylpyrazole 1194-02-1, 4-Fluorobenzonitrile 1206-37-7,
 4-[(Dimethylamino)sulfonyl]benzoic acid 1606-49-1, 1,4,5,6-
 Tetrahydropyrimidine 1664-40-0 1679-64-7, 4-(Methoxycarbonyl)benzoic
 acid 1779-81-3, 2-Amino-4,5-dihydrothiazole 2038-03-1,
 2-Morpholinoethylamine 2417-72-3, Methyl 4-(bromomethyl)benzoate
 2510-36-3, 3,5-Dimethyl-4-isoxazolecarboxylic acid 2749-11-3,
 (S)-2-Amino-1-propanol 2799-16-8 2799-17-9, (S)-1-Amino-2-propanol
 3144-09-0, Methanesulfonamide 3179-31-5, 4H-1,2,4-Triazole-3-thiol
 3222-47-7, 6-Methylnicotinic acid 3240-94-6, 4-(2-Chloroethyl)morpholine
 3524-32-1, 1,3-Dimethyl-1H-pyrazol-5-amine 3731-51-9,
 2-Aminomethylpyridine 3731-52-0, 3-Aminomethylpyridine 3731-53-1,
 4-Aminomethylpyridine 4025-64-3, 3-(Chlorosulfonyl)benzoic acid
 4066-41-5, 5-Acetylthiophene-2-carboxylic acid 4318-37-0,
 1-Methyl-1,4-diazepane 4318-76-7, 2,5-Diaminopyridine 4393-16-2,
 (4-(Methylsulfonyl)phenyl)methanamine 4403-69-4 4795-29-3,
 (Tetrahydrofuran-2-yl)methanamine 4916-55-6, 3-(Bromomethyl)pyridine
 hydrobromide 5036-48-6, 1-(3-Aminopropyl)imidazole 5188-07-8, Sodium
 thiomethoxide 5308-25-8, 1-Ethylpiperazine 5332-73-0,
 3-Methoxypropylamine 5345-27-7, 3-(Methylsulfonyl)benzoic acid
 5345-47-1, 2-Aminonicotinic acid 5350-93-6, 6-Chloropyridin-3-amine
 5382-16-1, 4-Piperidinol 5625-67-2, 3-Oxopiperazine 6068-72-0,
 4-Cyanobenzoyl chloride 6232-88-8, 4-(Bromomethyl)benzoic acid
 6283-25-6, 2-Chloro-5-nitroaniline 6302-65-4, Methyl 4-mercaptobenzoate
 6482-24-2, 2-Bromoethyl methyl ether 6628-77-9, 2-Methoxy-5-
 aminopyridine 7144-05-0, Piperidin-4-ylmethanamine 7154-73-6,
 N-(2-Aminoethyl)pyrrolidine 7170-01-6, 3-Methyl-1,2,4-triazole
 7175-81-7 7318-00-5, Ethyl 3-aminocrotonate 7663-77-6,
 1-(3-Aminopropyl)-2-pyrrolidinone 7697-27-0, 2-Bromo-4-methylbenzoic
 acid 7720-39-0, 2-Aminoimidazole 10130-89-9, 4-Chlorosulfonylbenzoic
 acid 10147-37-2, 2-Propanesulfonyl chloride 10272-07-8,
 3,5-Dimethoxyaniline 13324-11-3, Methyl 2-chloro-4-nitrobenzoate
 13889-98-0, N-Acetyl piperazine 13952-84-6, sec-Butylamine 14678-05-8,
 5-Aminoisoxazole 15448-47-2, reactions 15715-41-0, Diethyl
 methylphosphonite 16088-62-3, (S)-Propylene oxide, reactions
 16588-26-4, 3-Bromo-4-chloro-nitrobenzene 17213-57-9,
 3,5-Dimethoxybenzoyl chloride 17570-98-8, 2-(Bromoacetyl)pyridine
 hydrobromide 17616-04-5, 4-(1H-Imidazol-1-yl)benzoic acid 17874-79-2,
 5-(Methoxycarbonyl)picolinic acid 18358-63-9, Methyl
 4-(methylamino)benzoate 18643-86-2, Dimethyl 2-bromoterephthalate
 19721-22-3, 3-Mercapto-1-propanol 20780-53-4 20780-54-5, (S)-Styrene
 oxide 20989-17-7, (S)-2-Amino-2-phenylethanol 21035-59-6,
 N-Methyl-1-(pyridin-2-yl)methanamine 21655-48-1, cis-2,6-
 Dimethylpiperazine 23806-24-8, 3-Methyl-2-thiophenecarboxylic acid
 24665-93-8, 2-Amino-4,5-dihydrooxazole 24854-43-1, 4-Methyl-4H-1,2,4-
 triazole-3-thiol 30609-80-4, 4-(2-Hydroxyethylthio)benzonitrile
 31106-82-8, 2-(Bromomethyl)pyridine hydrobromide 31152-37-1, Thiazoline
 33233-67-9 38496-18-3, 2,6-Dichloronicotinic acid 40546-33-6,
 3-(1H-Imidazol-4-yl)propan-1-amine 41404-58-4, 5-Fluoro-2-bromopyridine
 41838-46-4, 4-Amino-1-methylpiperidine 42860-10-6, 3-Bromo-4-
 chlorobenzoic acid 49773-20-8, 2-(Methylsulfonyl)ethanamine
 50488-42-1, 5-Trifluoromethyl-2-bromopyridine 53250-83-2,
 2-Chloro-4-methylsulfonylbenzoic acid 54453-91-7, 4-Ethyl-2-
 bromopyridine 55276-43-2, 1-Methylsulfonylpiperazine 55715-03-2,
 4-(Bromomethyl)-3-nitrobenzoic acid 56613-80-0 57260-71-6
 58757-38-3, 6-Chloronicotinoyl chloride 60166-86-1, 5-
 (Methylsulfonyl)thiophene-2-carboxylic acid 60702-69-4,

2-Chloro-4-fluorobenzonitrile 67832-11-5, 4-Bromo-2-methylbenzonitrile
 73781-91-6, Methyl 6-chloronicotinate 74879-18-8, (S)-2-Methylpiperazine
 75336-86-6 76003-29-7, tert-Butyl 3-oxopiperazine-1-carboxylate
 78190-05-3, 4-(1H-Tetrazol-1-yl)benzoic acid 78358-86-8,
 1-(2-Bromoethyl)-1H-pyrrole 82145-97-9, Methyl 4-((pyridin-2-
 ylthio)methyl)benzoate 87412-10-0, 5-Chloropyridin-2-yl
 trifluoromethanesulfonate 89938-62-5, 2-Chloro-5-(methylsulfonyl)benzoic
 acid 99636-32-5, (S)-1-Methoxy-2-propylamine 103249-79-2,
 4-Methyl-2-phenyl-5-pyrimidinecarboxylic acid 113023-73-7,
 4-(1-Bromoethyl)benzoic acid 119071-57-7, 6-Chloropyridin-2-yl
 trifluoromethanesulfonate 126456-43-7, (1S,2R)-1-Amino-2,3-dihydro-1H-
 inden-2-ol 133710-77-7, 2-(Pyrrolidin-2-yl)ethanamine 136030-00-7,
 (1R,2S)-1-Amino-2,3-dihydro-1H-inden-2-ol 147969-86-6,
 4-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methyl)benzoic acid
 158580-87-1, Methyl 2-amino-4-(methylsulfonyl)benzoate 158581-07-8,
 Methyl 4-(methylsulfonyl)-2-nitrobenzoate 181772-16-7 192948-09-7,
 1,2,3-Benzothiadiazole-5-carboxylic acid 199535-00-7,
 4-(Methylsulfonylmethyl)benzoic acid 217073-76-2, 1-(4-Fluorophenyl)-5-
 methyl-1H-pyrazole-4-carboxylic acid 218777-23-2, 2-Pyridylzinc bromide
 243853-14-7, 1-(4,5-Dihydro-1H-imidazol-2-yl)-3,5-dimethyl-1H-pyrazole
 254910-60-6, 4-(3-Hydroxypropylthio)benzonitrile 257876-05-4,
 5-Methyl-2-pyridylzinc bromide 261635-98-7, 6-(Trifluoromethyl)-2-
 methylpyridine-3-carbonyl chloride 281232-20-0, 6-(1H-1,2,4-Triazol-1-
 yl)pyridine-3-carboxylic acid 308795-91-7, 3-Methyl-2-pyridylzinc
 bromide 308795-93-9, 4-Methyl-2-pyridylzinc bromide 308795-98-4,
 6-Methyl-2-pyridylzinc bromide 431888-57-2, 2-Chloro-4-
 (methoxycarbonyl)benzoic acid 431888-59-4, 4-(tert-Butoxycarbonyl)-3-
 chlorobenzoic acid 573764-31-5, 4-Chloro-3-iodoaniline 849774-31-8,
 3-(Triisopropylsilyloxy)pyridine 879088-63-8, 5-Acetyl-N-(4-chloro-3-
 iodophenyl)thiophene-2-carboxamide 879088-64-9 879088-65-0
 879088-66-1 879088-67-2 879088-68-3 879088-69-4 879088-70-7,
 5-Phenylpyridin-2-yl trifluoromethanesulfonate 879088-71-8 879088-72-9
 879088-73-0, Methyl 4-((2-hydroxypropylthio)methyl)benzoate 879088-74-1
 879088-75-2 879088-76-3 879088-77-4, 4-((4H-1,2,4-Triazol-3-
 ylsulfonyl)methyl)benzoic acid 879088-78-5, 4-((4-Methyl-4H-1,2,4-
 triazol-3-yl)sulfinyl)methyl)benzoic acid 879088-79-6,
 4-((4-Methyl-4H-1,2,4-triazol-3-yl)sulfonyl)methyl)benzoic acid
 879088-80-9, 4-(Bromomethyl)-N-(3-(pyridin-2-yl)phenyl)benzamide
 879088-81-0 879088-82-1, tert-Butyl 4-(bromomethyl)-2-chlorobenzoate
 879088-83-2, 4-Amino-N-(4-chloro-3-(pyridin-2-yl)phenyl)benzamide
 879088-84-3, Methyl 2-chloro-4-mercaptopbenzoate 879088-85-4,
 4-(2-Bromoethylsulfonyl)benzonitrile 879088-86-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylpyridines as inhibitors of hedgehog signaling)
 IT 879088-87-6 879088-88-7 879088-89-8, 4-((4H-1,2,4-Triazol-3-
 ylsulfinyl)methyl)benzoic acid
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylpyridines as inhibitors of hedgehog signaling)
 IT 3556-86-3P, Methyl 3-hydroxy-4-methylbenzoate 14186-60-8P, Dimethyl
 2-methylterephthalate 46004-37-9P, Methyl 4-amino-2-chlorobenzoate
 74534-15-9P, 1-Chloro-2-iodo-4-nitrobenzene 88089-94-5P, Methyl
 4-(bromomethyl)-3-nitrobenzoate 116934-87-3P, 4-(Methoxycarbonyl)-3-
 methylbenzoic acid 158580-55-3P 199535-75-6P, Methyl
 4-(methylsulfonylmethyl)-3-nitrobenzoate 204568-74-1P, Methyl
 3-acetoxy-4-methylbenzoate 220504-68-7P, Methyl 3-acetoxy-4-
 (bromomethyl)benzoate 431888-58-3P 879088-40-1P, 4-Chloro-3-(pyridin-2-
 yl)nitrobenzene 879088-41-2P 879088-42-3P, 3-[3,5-
 Bis(trifluoromethyl)phenyl]-1-bromopropane 879088-43-4P,
 4-(Ethylsulfonylmethyl)benzoic acid 879088-44-5P, 4-(Dimethylcarbamoyl)-
 2-methylbenzoic acid 879088-45-6P, 6-(tert-Butylcarbamoyl)nicotinic acid
 879088-46-7P, 6-(Pyridin-2-ylmethylcarbamoyl)nicotinic acid
 879088-47-8P, 6-(Benzylcarbamoyl)nicotinic acid 879088-48-9P,
 6-(6-Methoxypyridin-3-ylcarbamoyl)nicotinic acid 879088-49-0P, Methyl

4-((2-hydroxypropylsulfonyl)methyl)benzoate 879088-50-3P,
 4-((2-Hydroxypropylsulfonyl)methyl)benzoic acid 879088-51-4P
 879088-52-5P 879088-53-6P 879088-54-7P 879088-55-8P, Methyl
 3-acetoxy-4-(methylsulfonylmethyl)benzoate 879088-56-9P,
 3-Hydroxy-4-(methylsulfonylmethyl)benzoic acid 879088-57-0P
 879088-58-1P 879088-59-2P, 4-(Methylsulfonylmethyl)-3-nitrobenzoic acid
 879088-60-5P 879088-61-6P 879088-62-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of arylpyridines as inhibitors of hedgehog signaling)

L8 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Compounds for inhibiting copper-containing amine oxidases and their use in
 inflammatory disease
 AN 2006:116947 CAPLUS
 DN 144:205758
 TI Compounds for inhibiting copper-containing amine oxidases and their use in
 inflammatory disease
 IN Olarte, Antonio Zorzano; Mian, Alec; Clauzel, Luc Marti; Exposito, Miriam
 Royo; Font, Francesc Yraola; Palomera, Fernando Albericio
 PA Genmedica Therapeutics SL, Spain
 SO PCT Int. Appl., 78 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006013209	A2	20060209	WO 2005-EP53778	20050802
	WO 2006013209	A3	20060615		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

US 2004-598010P P 20040802

OS MARPAT 144:205758

AB The present invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein- 1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.

IT Inflammation

(Crohn's disease; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Intestine, disease

(Crohn's; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Blood vessel, disease

(Raynaud's phenomenon; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Tinea (skin disease)

(Tinea versicolor, pityriasis rosea; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Proteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(VAP-1 (vascular adhesion protein 1), inhibitors; compds. for
inhibiting copper-containing amine oxidases and their uses)

IT Pain
Respiratory distress syndrome
(acute; compds. for inhibiting copper-containing amine oxidases and their
uses)

IT Adipose tissue
(adipocyte, dysfunction; compds. for inhibiting copper-containing amine
oxidases and their uses)

IT Inflammation
Spinal column, disease
(ankylosing spondylitis; compds. for inhibiting copper-containing amine
oxidases and their uses)

IT Antiarteriosclerotics
(antiatherosclerotics; compds. for inhibiting copper-containing amine
oxidases and their uses)

IT Mouth, disease
(aphthous ulcer; compds. for inhibiting copper-containing amine oxidases
and their uses)

IT Ulcer
(aphthous; compds. for inhibiting copper-containing amine oxidases and
their uses)

IT Inflammation
Stomach, disease
(atrophic gastritis; compds. for inhibiting copper-containing amine
oxidases and their uses)

IT Infection
(bacterial, *Helicobacter pylori*; compds. for inhibiting copper-containing
amine oxidases and their uses)

IT Bronchi, disease
Inflammation
(bronchitis; compds. for inhibiting copper-containing amine oxidases and
their uses)

IT Ischemia
(cardiac; compds. for inhibiting copper-containing amine oxidases and their
uses)

IT Pain
(central origin; compds. for inhibiting copper-containing amine oxidases
and their uses)

IT Lung, disease
(chronic obstructive pulmonary disease; compds. for inhibiting
copper-containing amine oxidases and their uses)

IT Inflammation
Lung, disease
(chronic pneumonitis; compds. for inhibiting copper-containing amine
oxidases and their uses)

IT Dermatitis
(chronic; compds. for inhibiting copper-containing amine oxidases and their
uses)

IT Alzheimer's disease
Analgesics
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antiasthmatics
Antidiabetic agents
Antiglaucoma agents
Antihypertensives
Antiobesity agents
Antiparkinsonian agents
Antipyretics
Antirheumatic agents

- Antitumor agents
- Antiulcer agents
- Arthritis
- Asthma
- Atherosclerosis
- Bacteremia
- Blood vessel, disease
- Bone resorption
- Bone resorption inhibitors
- Celiac disease
- Cystic fibrosis
- Diabetes mellitus
- Digestive tract, disease
- Disease, animal
- Drug delivery systems
- Eczema
- Endotoxemia
- Fever and Hyperthermia
- Gastrointestinal agents
- Glaucoma (disease)
- Gout
- Human
- Hypertension
- Immune disease
- Inflammation
- Meningitis
- Multiple sclerosis
- Neoplasm
- Nervous system agents
- Obesity
- Osteoarthritis
- Parkinson's disease
- Periodontium, disease
- Psoriasis
- Rheumatoid arthritis
- Sepsis
- (compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Carbohydrate metabolism
- RL: BSU (Biological study, unclassified); BIOL (Biological study)
- (compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Eye, disease
- Inflammation
- (conjunctivitis; compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Nervous system, disease
- (degeneration; compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Hydroxamic acids
- RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (derivs.; compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Lung, disease
- (farmer's lung; compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Inflammation
- Stomach, disease
- (gastritis, varioliform; compds. for inhibiting copper-containing amine oxidases and their uses)
- IT Gingiva, disease
- Inflammation
- (gingivitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Inflammation
Intestine, disease
(ileitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Helicobacter pylori
(infection; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Central nervous system, disease
(inflammation; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Pain
(inflammatory pain; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Intestine, disease
(inflammatory; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Reperfusion
(injury, ischemia; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Intestine, disease
(irritable bowel syndrome; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Heart, disease
(ischemia; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Skin, disease
(lichen planus; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Angiogenesis
(neovascularization, retinal; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Nerve, disease
Pain
(neuralgia; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Nerve, disease
(neuropathy; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Eye, disease
Inflammation
(ophthalmitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Inflammation
Pancreas, disease
(pancreatitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Ulcer
(peptic; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Inflammation
Lung, disease
(pneumonitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Arthritis
(psoriatic arthritis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Esophagus, disease
Inflammation
(reflux esophagitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Injury
(reperfusion, ischemia; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Eye, disease
(retina, neovascularization; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Shock (circulatory collapse)
(septic; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Inflammation
Spinal column, disease
(spondylitis, rheumatoid; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Brain, disease
(stroke; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Digestive tract, disease
(ulcer, peptic; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Foot
(ulcer; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Inflammation
Intestine, disease
(ulcerative colitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT Eye, disease
Inflammation
(uveitis; compds. for inhibiting copper-containing amine oxidases and their uses)

IT 875518-37-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for inhibiting copper-containing amine oxidases and their uses)

IT 116408-48-1P 130289-49-5P 154737-59-4P 327037-09-2P 327037-34-3P
875518-38-0P 875518-39-1P 875518-40-4P 875518-41-5P 875518-42-6P
875518-43-7P 875518-44-8P 875518-45-9P 875518-46-0P 875518-47-1P
875518-48-2P 875518-49-3P 875518-50-6P 875518-51-7P 875518-52-8P
875518-53-9P 875518-54-0P 875518-55-1P 875518-56-2P 875518-57-3P
875518-58-4P 875518-59-5P 875518-60-8P 875518-61-9P 875518-62-0P
875518-63-1P 875518-64-2P 875518-65-3P 875518-66-4P 875518-67-5P
875518-68-6P 875518-69-7P 875518-70-0P 875518-71-1P 875518-72-2P
875518-73-3P 875518-74-4P 875518-75-5P 875518-76-6P 875518-77-7P
875518-78-8P 875518-79-9P 875518-80-2P 875518-81-3P 875518-82-4P
875518-83-5P 875518-84-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for inhibiting copper-containing amine oxidases and their uses)

IT 174777-70-9 301527-63-9 471924-87-5 591217-29-7 591217-38-8
656261-21-1 875518-85-7 875518-86-8 875518-87-9 875518-88-0
875518-89-1 875518-90-4 875518-91-5 875518-92-6 875518-93-7
875518-94-8 875518-95-9 875518-96-0 875518-97-1 875518-98-2
875518-99-3 875519-00-9 875519-01-0 875519-02-1 875519-03-2
875519-04-3 875519-05-4 875519-06-5 875519-07-6 875519-08-7
875519-09-8 875519-10-1 875519-11-2 875519-12-3 875519-13-4
875519-14-5 875519-15-6 875519-16-7 875519-17-8 875519-18-9
875519-19-0 875519-20-3 875519-21-4 875519-22-5 875519-23-6
875519-24-7 875519-25-8 875519-26-9 875519-27-0 875519-28-1
875519-29-2 875519-30-5 875519-31-6 875519-32-7 875519-33-8
875519-34-9 875519-35-0 875519-36-1 875519-37-2 875519-38-3
875519-39-4 875519-40-7 875519-41-8 875519-42-9 875519-43-0
875519-44-1 875519-45-2 875519-46-3 875519-47-4 875519-48-5
875519-49-6 875519-50-9 875519-51-0 875519-52-1 875519-53-2
875519-54-3 875519-55-4 875519-56-5 875519-57-6 875519-58-7

875519-59-8	875519-60-1	875519-61-2	875519-62-3	875519-63-4
875519-64-5	875519-65-6	875519-66-7	875519-67-8	875519-68-9
875519-69-0	875519-70-3	875519-71-4	875519-72-5	875519-73-6
875519-74-7	875519-75-8	875519-76-9	875519-77-0	875519-78-1
875519-79-2	875519-80-5	875519-81-6	875519-82-7	875519-83-8
875519-84-9	875519-85-0	875519-86-1	875519-87-2	875519-88-3
875519-89-4	875519-90-7	875519-91-8	875519-92-9	875519-93-0
875519-94-1	875519-95-2	875519-96-3	875519-97-4	875519-98-5
875519-99-6	875520-00-6	875520-01-7	875520-02-8	875520-03-9
875520-04-0	875520-05-1	875520-06-2	875520-07-3	875520-08-4
875520-09-5	875520-10-8	875520-11-9	875520-12-0	875520-13-1
875520-14-2	875520-15-3	875520-16-4	875520-17-5	
875520-18-6	875520-19-7	875520-20-0	875520-21-1	
875520-22-2	875520-23-3	875520-24-4	875520-25-5	
875520-26-6	875520-27-7	875520-28-8	875520-29-9	
875520-30-2	875520-31-3	875520-32-4	875520-33-5	
875520-34-6	875520-35-7	875520-36-8	875520-37-9	
875520-38-0	875520-39-1	875520-40-4	875520-41-5	
875520-42-6	875520-43-7	875520-44-8	875520-45-9	
875520-46-0	875520-47-1	875520-48-2	875520-49-3	
875520-50-6	875520-51-7	875520-52-8	875520-53-9	875520-54-0
875520-55-1	875520-56-2	875520-57-3	875520-58-4	875520-59-5
875520-60-8	875520-61-9	875520-62-0	875520-63-1	875520-64-2
875520-65-3	875520-66-4	875520-67-5	875520-68-6	875520-69-7
875520-70-0	875520-71-1	875520-72-2	875520-73-3	875520-74-4
875520-75-5	875520-76-6	875520-77-7	875520-78-8	875520-79-9
875520-80-2	875520-81-3	875520-82-4	875520-83-5	875520-84-6
875520-85-7	875520-86-8	875520-87-9	875520-88-0	875520-89-1
875520-90-4	875520-91-5	875520-92-6	875520-93-7	875520-94-8
875520-95-9	875520-96-0	875520-97-1	875520-98-2	875520-99-3
875521-00-9	875521-01-0	875521-02-1	875521-03-2	875521-04-3
875521-05-4	875521-06-5	875521-07-6	875521-08-7	875521-09-8
875521-10-1	875521-11-2	875521-12-3	875521-13-4	875521-14-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compds. for inhibiting copper-containing amine oxidases and their uses)

IT 875521-15-6 875521-16-7 875521-17-8 875521-18-9 875521-19-0
875521-20-3 875521-21-4 875521-22-5 875521-23-6 875521-24-7
875521-25-8 875521-26-9 875521-27-0 875521-28-1 875521-29-2
875521-30-5 875521-31-6 875521-32-7 875521-33-8 875521-34-9
875521-35-0 875521-36-1 875521-37-2 875521-38-3 875521-39-4
875521-40-7 875521-41-8 875521-42-9 875521-43-0 875521-44-1
875521-45-2 875521-46-3 875521-47-4 875521-48-5 875521-49-6
875521-50-9 875521-51-0 875521-52-1 875521-53-2 875521-54-3
875521-55-4 875521-56-5 875521-57-6 875521-58-7 875521-59-8
875521-60-1 875521-61-2 875521-62-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compds. for inhibiting copper-containing amine oxidases and their uses)

IT 108-30-5, Succinic anhydride, reactions 5470-11-1 26588-35-2,
Biphenylsulfonyl chloride 160450-13-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(compds. for inhibiting copper-containing amine oxidases and their uses)

IT 9001-53-0, Copper-containing amine oxidase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, Semicarbazide-sensitive; compds. for inhibiting
copper-containing amine oxidases and their uses)

L8 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of tetrahydronaphthalene hydroxamates and benzamides as
histone deacetylase (HDAC) inhibitors.


AN 2005:516308 CAPLUS

DN 143:43695

TI Preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase (HDAC) inhibitors.
 IN Leblond, Bertrand; Beausoleil, Eric
 PA Exonhit Therapeutics S.A., Fr.
 SO Eur. Pat. Appl., 50 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1541549	A1	20050615	EP 2003-293143	20031212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	WO 2005058803	A1	20050630	WO 2004-IB4334	20041210
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1692097	A1	20060823	EP 2003-293143	A 20031212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			EP 2004-806498	20041210
				EP 2003-293143	A 20031212
				WO 2004-IB4334	W 20041210

OS MARPAT 143:43695
 GI



AB Title compds. [I; R = CONR7R8, COCONR8R9, COCONHMe, COCF3, etc.; R7 = OH, OR9, 2-aminophenyl; R8, R9 = H, alkyl; X1 = C, O, N, S; R1, R2 = null, H, alkyl, 1-2 O; X2, X3 = CH, O, N; X2X3 = S, O, N; X4 = N, CH; R3-R5 = H, OH, NH2, halo, alkyl, perfluoroalkyl, etc.; L = alkylene, alkenylene, alkynylene, (aromatic) cycloalkyl, O, CO, CONH, CF2CONH, SO2NH, NMeSO2, etc.], were prepared. Thus, 4-[2,2-difluoro-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)acetylamino]benzoic acid (preparation given) was stirred with SOCl2 and cat. DMF at 0° for 1 h. The residue in CH2Cl2 was added to a mixture prepared from hydroxylamine hydrochloride, H2O, and Et3N in THF at 0° followed by stirring at 0° for 10 min. and at room temperature for 17.75 h to give 33.4% 4-[2,2-difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido]-N-hydroxybenzamide (EHT 9299). The latter showed HDAC inhibitory activity with IC50 = 424 nM.

IT Nervous system, disease
 (Huntington's chorea, treatment; preparation of tetrahydronaphthalene

hydroxamates and benzamides as histone deacetylase inhibitors)

IT Nervous system, disease
(amyotrophic lateral sclerosis, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Intestine, neoplasm
(colon, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Liver, disease
(fibrosis, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Neoplasm
Neoplasm
(head and neck, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Fibrosis
(hepatic, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Nerve, disease
(ischemia, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Ischemia
(neuronal, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Lymphoma
(non-Hodgkin's, treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Drug delivery systems
Human
(preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT Acute promyelocytic leukemia
Alzheimer's disease
Bladder, neoplasm
Cirrhosis
Head and Neck, neoplasm
Head and Neck, neoplasm
Liver, neoplasm
Lung, neoplasm
Mammary gland, neoplasm
Melanoma
Multiple sclerosis
Neoplasm
Ovary, neoplasm
Pancreas, neoplasm
Parkinson's disease
Prostate gland, neoplasm
Psoriasis
(treatment; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT 149647-78-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(EHT 0648, reference compound; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT 149648-52-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Suberanic acid; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT 853728-52-6P, N-(4-(Hydroxycarbamoyl)phenyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethylnaphthalene-2-carboxamide 853728-53-7P, N-(4-(2-

Aminophenylcarbamoyl)phenyl)-5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-naphthalene-2-carboxamide 853728-54-8P 853728-55-9P
853728-56-0P 853728-57-1P, 4-(2,2-Difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)-N-hydroxybenzamide 853728-58-2P,
3-(2,2-Difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)-N-hydroxybenzamide 853728-59-3P, 4-((2,2-Difluoro-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-7-yl)acetamido)methyl)-N-hydroxybenzamide 853728-60-6P 853728-61-7P, N-(4-Hydroxycarbamoylphenyl)-N'-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)oxalamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT 56-91-7, 4-Aminomethylbenzoic acid 62-53-3, Aniline, reactions
95-54-5, 1,2-Phenylenediamine, reactions 505-48-6, Suberic acid
540-37-4, 4-Iodophenylamine 619-45-4, Methyl 4-aminobenzoate 667-27-6,
Ethyl bromodifluoroacetate 1571-08-0, Methyl 4-formylbenzoate
1679-64-7, Terephthalic acid monomethyl ester 4518-10-9, Methyl
3-aminobenzoate 5781-53-3, Methyl oxalyl chloride 6683-46-1,
1,1,4,4-Tetramethyl-1,2,3,4-tetrahydronaphthalene 6683-48-3,
1,1,4,4,6-Pentamethyl-1,2,3,4-tetrahydronaphthalene

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

IT 10521-06-9P, 2,9-Oxonanedione 18469-52-8P, Methyl 4-(aminomethyl)benzoate 92050-16-3P, 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-ylamine 94497-53-7P 102121-54-0P
102121-59-5P 102121-60-8P 103031-30-7P, 5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalene-2-carboxylic acid 119435-90-4P 119436-52-1P
119436-53-2P 119454-82-9P 121866-06-6P 168301-01-7P 168301-02-8P
853728-62-8P 853728-63-9P 853728-64-0P 853728-65-1P 853728-66-2P
853728-67-3P 853728-68-4P 853728-69-5P 853728-70-8P 853728-71-9P
853728-72-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tetrahydronaphthalene hydroxamates and benzamides as histone deacetylase inhibitors)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.

AN 2005:182616 CAPLUS

DN 142:279954

TI Preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging.

IN Rho, Ho Sik; Baek, Heung Soo; Kim, Su Jong; Kim, Su Nam; Chae, Byung Geun; Lee, Byoung Seok; Kim, Bae Hwan; Choi, Gyu Ho; Son, Eui Dong; Lee, Hae Kwang; Lee, Hye Won; Cho, Jun-cheol; Kim, Duck Hee; Chang, Ih Seop; Lee, Ok Sub

PA Amorepacific Corporation, S. Korea

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005019162	A1	20050303	WO 2004-KR2143	20040826



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
KR 2006005892	A	20060118	KR 2004-54886		20040714
EP 1660437	A1	20060531	EP 2004-774404		20040826
R: FR					

			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
			WO 2004-KR2143	W	20040826
CN 1839115	A	20060927	CN 2004-80024139		20040826
			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
			WO 2004-KR2143	W	20040826
US 2006252834	A1	20061109	US 2006-595124		20060615
			KR 2003-59177	A	20030826
			KR 2004-20401	A	20040325
			KR 2004-54886	A	20040714
			WO 2004-KR2143	W	20040826

OS MARPAT 142:279954
 GI



AB Title compds. [I; R1 = adamantyl, Q1; R5, R6 = H, alkyl, cycloalkyl; R2 = CONH, NHCO, CONR7, NR7CO; R7 = alkyl; R3 = (CH)_n; n = 0, 1; R4 = H, alkyl], were prepared Thus, 4-(phenylcarbonylamino)benzoic acid (preparation given) in pyridine at 10° was treated dropwise with Et chloroformate followed by stirring for 2 h at room temperature to give the anhydride. This was added to NH₂OH.HCl in pyridine at 10° followed by stirring for 30 min. to give 65% N-[4-(N-hydroxycarbamoyl)phenyl]benzamide. The latter reduced collagenase expression in vitro to 78% of controls, vs. 85% for retinol.

IT Cosmetics

(creams, wrinkle-preventing; preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT Retinoid receptors

RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (ligands; preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT Cosmetics

(preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT Hydroxamic acids

RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT 9001-12-1, Collagenase 9004-06-2, Elastase
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (expression inhibitors; preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT 149648-29-3P 475557-69-8P 475557-71-2P 847249-45-0P
 847249-48-3P 847249-49-4P 847249-51-8P 847249-53-0P 847249-55-2P
 847249-57-4P 847249-59-6P 847249-61-0P 847249-63-2P 847249-65-4P
 847249-67-6P 847249-69-8P 847249-71-2P 847249-73-4P 847249-75-6P
 847249-77-8P 847249-79-0P 847249-81-4P 847249-83-6P 847249-86-9P
 847249-88-1P 847249-91-6P 847249-93-8P 847249-95-0P 847249-97-2P
 847249-99-4P 847250-01-5P 847250-03-7P 847250-05-9P 847250-07-1P
 847250-09-3P 847250-11-7P 847250-13-9P
 847250-15-1P 847250-17-3P 847250-19-5P
 847250-21-9P 847250-23-1P 847250-25-3P
 847250-27-5P 847250-29-7P 847250-31-1P 847250-33-3P 847250-35-5P
 847250-37-7P 847250-39-9P 847250-41-3P 847250-43-5P 847250-45-7P
 847250-47-9P 847250-49-1P
 RL: COS (Cosmetic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT 62-53-3, Aniline, reactions 65-85-0, Benzoic acid, reactions 95-64-7, 3,4-Dimethylaniline 98-73-7, 4-tert-Butylbenzoic acid 99-04-7, 3-Methylbenzoic acid 99-88-7, 4-Isopropylaniline 99-94-5, 4-Methylbenzoic acid 104-13-2, 4-Butylaniline 106-49-0, 4-Methylaniline, reactions 108-44-1, 3-Methylaniline, reactions 536-66-3, 4-Isopropylbenzoic acid 589-16-2, 4-Ethylaniline 619-04-5, 3,4-Dimethylbenzoic acid 619-45-4, Methyl 4-aminobenzoate 619-64-7, 4-Ethylbenzoic acid 768-94-5, Adamantanamine 769-92-6, 4-tert-Butylaniline 1679-64-7, Monomethylterephthalate 2438-05-3, 4-Propylbenzoic acid 2696-84-6, 4-Propylaniline 3814-10-6 4229-44-1, N-Methylhydroxylamine hydrochloride 5470-11-1 20651-71-2, 4-Butylbenzoic acid 39552-81-3, 4-Aminophenylacetic acid methyl ester 42862-36-2, Adamantanecarboxylic acid 102121-29-9 102121-30-2 121768-34-1 156811-44-8 159045-80-4 300667-13-4 303790-73-0 329940-82-1 544422-90-4 839697-12-0 847250-58-2 847250-61-7 847250-68-4 847250-70-8 847250-72-0 847250-75-3 847250-78-6 847250-80-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

IT 93-97-0P, Benzoic anhydride 582-80-9P 39799-73-0P 51774-36-8P 847250-53-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of arylhydroxamates as elastase and collagenase expression inhibitors for preventing skin aging)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of thiophenedicarboxamides and related compounds as histone deacetylase (HDAC) inhibitors.
 AN 2003:43028 CAPLUS
 DN 138:106596
 TI Preparation of thiophenedicarboxamides and related compounds as histone deacetylase (HDAC) inhibitors.
 IN Leser-Reiff, Ulrike; Sattelkau, Tim; Zimmermann, Gerd
 PA Hoffman-La Roche, Inc., Germany

SO U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003013757	A1	20030116	US 2002-167677	20020611
	US 6784173	B2	20040831		
	CA 2449804	A1	20030213	EP 2001-114496	A 20010615
				CA 2002-2449804	20020613
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613
	WO 2003011851	A2	20030213	WO 2002-EP6488	20020613
	WO 2003011851	A3	20030918		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1401824	A2	20040331	EP 2001-114496	A 20010615
	EP 1401824	B1	20061025	EP 2002-791436	20020613
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613
CN	1516697	A	20040728	CN 2002-812010	20020613
BR	2002010424	A	20040817	EP 2001-114496	A 20010615
				BR 2002-10424	20020613
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613
NZ	529874	A	20041224	NZ 2002-529874	20020613
JP	2005502641	T	20050127	EP 2001-114496	A 20010615
				JP 2003-517043	20020613
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613
AT	343569	T	20061115	AT 2002-791436	20020613
RU	2289580	C2	20061220	EP 2001-114496	A 20010615
				RU 2003-137578	20020613
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613
ZA	2003009260	A	20050228	ZA 2003-9260	20031127
IN	2003CN01981	A	20060106	EP 2001-114496	A 20010615
				IN 2003-CN1981	20031211
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613
BG	108450	A	20050131	BG 2003-108450	20031215
US	2004214862	A1	20041028	EP 2001-114496	A 20010615
				US 2004-847166	20040517
				EP 2001-114496	A 20010615
				US 2002-167677	A3 20020611
HK	1065787	A1	20061117	HK 2004-108497	20041029
				EP 2001-114496	A 20010615
				WO 2002-EP6488	W 20020613

OS MARPAT 138:106596

AB HONHCOACONR1R2 [A = (substituted) Ph, thienyl; R1, R2 = H, (substituted) alkyl, carbocyclyl, heterocyclyl; NR1R2 = (substituted) 3-6 membered

ring], were prepared. Thus, thiophene-2,5-dicarboxylic acid monomethyl ester and N-methylmorpholine in CH₂Cl₂ at -10° were treated with 1-aminomethylnaphthalene in CH₂Cl₂; the mixture was stirred 90 min to give 58% monoamide. This was stirred with NH₂OH.HCl and NaOMe in MeOH for 4 h to give thiophene-2,5-dicarboxylic acid 2-hydroxyamide 5-[(naphthalen-1-ylmethyl)amide]. Tested title compds. inhibited HT-29 tumor cell growth with IC₅₀ = 0.02-0.17 μM. A tablet formulation is given.

IT Antitumor agents

Human

(preparation of thiophenedicarboxamides and related compds. as histone deacetylase (HDAC) inhibitors)

IT Neoplasm

(treatment; preparation of thiophenedicarboxamides and related compds. as histone deacetylase (HDAC) inhibitors)

IT	487002-77-7P	487002-78-8P	487002-79-9P	487002-80-2P	487002-81-3P
	487002-82-4P	487002-83-5P	487002-84-6P	487002-85-7P	487002-86-8P
	487002-87-9P	487002-88-0P	487002-89-1P	487002-90-4P	487002-91-5P
	487002-92-6P	487002-93-7P	487002-94-8P	487002-95-9P	487002-96-0P
	487002-98-2P	487003-00-9P	487003-02-1P	487003-04-3P	487003-05-4P
	487003-07-6P	487003-09-8P	487003-11-2P	487003-13-4P	487003-15-6P
	487003-17-8P	487003-19-0P	487003-21-4P	487003-23-6P	487003-25-8P
	487003-26-9P	487003-28-1P	487003-30-5P	487003-32-7P	487003-34-9P
	487003-36-1P	487003-37-2P	487003-38-3P	487003-39-4P	487003-40-7P
	487003-41-8P	487003-42-9P	487003-43-0P	487003-44-1P	487003-45-2P
	487003-46-3P	487003-47-4P	487003-48-5P	487003-49-6P	487003-50-9P
	487003-51-0P	487003-52-1P	487003-53-2P	487003-54-3P	487003-55-4P
	487003-56-5P	487003-57-6P	487003-58-7P	487003-59-8P	487003-60-1P
	487003-61-2P	487003-62-3P	487003-63-4P	487003-64-5P	487003-65-6P
	487003-66-7P	487003-67-8P	487003-68-9P	487003-69-0P	487003-70-3P
	487003-71-4P	487003-72-5P	487003-73-6P	487003-74-7P	487003-75-8P
	487003-76-9P	487003-77-0P	487003-78-1P	487003-79-2P	487003-80-5P
	487003-81-6P	487003-82-7P	487003-83-8P	487003-84-9P	487003-85-0P
	487003-86-1P	487003-87-2P	487003-88-3P	487003-89-4P	487003-90-7P
	487003-91-8P	487003-92-9P	487003-93-0P	487003-94-1P	487003-95-2P
	487003-96-3P	487003-97-4P	487003-98-5P	487003-99-6P	487004-00-2P
	487004-01-3P	487004-02-4P	487004-03-5P	487004-04-6P	487004-05-7P
	487004-06-8P	487004-07-9P	487004-08-0P	487004-09-1P	487004-10-4P
	487004-11-5P	487004-12-6P	487004-13-7P	487004-14-8P	487004-15-9P
	487004-16-0P	487004-17-1P	487004-18-2P	487004-19-3P	487004-20-6P
	487004-21-7P	487004-22-8P	487004-23-9P	487004-24-0P	487004-25-1P
	487004-26-2P	487004-27-3P	487004-28-4P	487004-29-5P	487004-30-8P
	487004-31-9P	487004-32-0P	487004-33-1P	487004-34-2P	487004-35-3P
	487004-36-4P	487004-37-5P	487004-38-6P	487004-39-7P	487004-40-0P
	487004-41-1P	487004-42-2P	487004-43-3P	487004-44-4P	487004-45-5P
	487004-46-6P	487004-47-7P	487004-48-8P	487004-49-9P	487004-50-2P
	487004-51-3P	487004-52-4P	487004-53-5P	487004-54-6P	
	487004-55-7P	487004-56-8P	487004-57-9P	487004-58-0P	487004-59-1P
	487004-60-4P	487004-61-5P	487004-62-6P	487004-64-8P	
	487004-65-9P	487004-66-0P	487004-67-1P	487004-68-2P	
	487004-71-7P	487004-73-9P	487004-75-1P	487004-77-3P	487004-79-5P
	487004-81-9P	487004-82-0P	487004-84-2P	487004-86-4P	487004-88-6P
	487004-89-7P	487004-90-0P	487004-91-1P	487004-92-2P	487004-93-3P
	487004-95-5P	487004-97-7P	487010-28-6P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of thiophenedicarboxamides and related compds.

as histone deacetylase (HDAC) inhibitors)

IT 9076-57-7, Histone deacetylase

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(inhibitors; preparation of thiophenedicarboxamides and related compds. as

histone deacetylase (HDAC) inhibitors)

IT 100-21-0, Terephthalic acid, reactions 118-31-0, 1-Aminomethylnaphthalene 622-33-3, O-Benzylhydroxylamine 3858-80-8, 3,5-Dimethylbenzylamine 4152-90-3, 3-Chlorobenzylamine 18469-52-8, Methyl 4-aminomethylbenzoate 50340-79-9, Thiophene-2,5-dicarboxylic acid monomethyl ester 487005-05-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiophenedicarboxamides and related compds. as histone deacetylase (HDAC) inhibitors)

IT 487004-98-8P 487004-99-9P 487005-01-6P 487005-02-7P 487005-07-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiophenedicarboxamides and related compds. as histone deacetylase (HDAC) inhibitors)

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

AN 2002:736103 CAPLUS

DN 137:247516

TI Preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

IN Naka, Masao; Takahashi, Kanji

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2

DT Patent


LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074298	A1	20020926	WO 2002-JP2681	20020320
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005119305	A1	20050602	JP 2001-81302	A 20010321
			US 2003-472160	20030922
			JP 2001-81302	A 20010321
			WO 2002-JP2681	W 20020320

OS MARPAT 137:247516

GI



AB Interleukin 6 (IL-6) production inhibitors containing as the active ingredient hydroxamic acid derivs. (I) or equivalent thereto, non-toxic salts thereof or prodrugs of the same [R1 = C1-8 alkyl, C2-8 alkenyl or alkynyl, halo, NO2, cyano, CF3, CF3O, OR2, SR2, NR3R4, keto, cyclic group, COR5, SO2R10,

SOR10, etc. (wherein R2-R4 = H, C1-8 alkyl, C2-9 acyl, cyclic group; R5 = HO, C1-8 alkyl or alkoxy, optionally substituted NH2, cyclic group; R10 = C1-8 alkyl, cyclic group); A = single bond, C3-15 mono-, di-, or tricyclic carbocyclic ring, 5- to 18-membered mono-, di-, or tricyclic heterocyclic ring containing 1-4 N, 1-2 O and/or 1-2 S atoms; E = a single bond, C1-8 alkylene, C2-8 alkenylene or alkynylene, O, SO2NH, NHSO2, CONH, NHCO, etc.; B = s single bond, C5-15 mono-, di-, or tricyclic carbocyclic ring; 5- to 18-membered mono-, di-, or tricyclic heterocyclic ring containing 1-4 N, 1-2 O and/or 1-2 S atoms; R8 = C1-8 alkyl or alkoxy, halo, NO2, cyano, CF3, CF3O, HO, C1-8 hydroxyalkyl; when E is a single bond, R1 and R8 together represents a C1-4 alkylene; n = an integer of 1-5; G = a single bond, (un)substituted NHCO or CONH, O, S, SO, SO2, (un)substituted SO2NH, CO, etc.; L = C1-8 alkylene, C2-8 alkenylene or alkynylene, C2-8 alkenylene-C2-8 alkynylene, C2-8 alkylene-C2-8 alkenylene, etc.; Q = (un)substituted CONHOH, oxiranylcabonyl, (un)substituted SH, P(O)(OH)2 or its C1-4 alkyl ester; some proviso are given] are claimed. Because of having an IL-6 production inhibitory activity, the compds. of the general formula I are useful as preventives and/or remedies for various inflammatory diseases, sepsis, multiple myeloma, plasmacytoid leukemia, osteoporosis, cachexia, psoriasis, nephritis, kidney cell cancer, Kaposi's sarcoma, rheumatoid arthritis, hypergamma globulinemia, Castleman's disease, intra-atrial myxoma, diabetes, autoimmune diseases, hepatitis, colitis, graft-vs.-host disease, infections, endometriosis and solid cancer. The solid cancer include brain tumor, head and neck cancer, thyroid gland cancer, esophageal cancer, stomach cancer, colorectal cancer (colon cancer and rectum cancer), liver cancer, gallbladder cancer, bile duct cancer (cholangioma), pancreatic cancer, lung cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, prostatic cancer, testicular tumor, bladder cancer, renal pelvis tumor, ureteral tumor, adrenal cancer (hypernephroma), neuroma, glioma, bone tumor, rhabdomyosarcoma, osteosarcoma, soft tissue tumor, eosinophilic granuloma, malignant melanoma, skin cancer, Wilms's tumor, etc. Thus, to a solution of 2.24 g 6-[(4-phenylbenzoyl)amino]hexanoic acid in 42 mL DMF were successively added 1-hydroxybenzotriazole hydrate 1.65, Et3N 2.91, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 2.07, and N-(1-methyl-1-methoxyethoxy)amine 1.14 g and stirred at room temperature for 4

h

to give 1.79 g N-(1-methyl-1-methoxyethoxy)-6-[(4-phenylbenzoyl)amino]hexanamide which (1.78 g) was dissolved in 4.5 mL MeOH and stirred with 4.5 mL 2 N aqueous HCl at room temperature to give N-hydroxy-6-[(4-phenylbenzoyl)amino]hexanamide (II). II in vitro inhibited the production of IL-6 in human lung epithelial cell A549 with IC50 of 0.18 μ M. A tablet and an ampule formulation containing II were prepared

IT Lymph node, disease

(Castleman's; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Sarcoma

(Kaposi's; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Kidney, neoplasm

(Wilms'; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Uterus, neoplasm

(cervix; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Bile duct, neoplasm

(cholangioma; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Inflammation

Intestine, disease

(colitis; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

inhibitors as preventives and/or remedies for diseases)

IT Intestine, neoplasm
(colon; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Intestine, neoplasm
(colorectal; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Uterus, disease
(endometriosis; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Granuloma
(eosinophilic; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Transplant and Transplantation
(graft-vs.-host reaction; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Neoplasm
(head and neck, head and neck; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Head and Neck, neoplasm
(head and neck; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Heart, disease
(intra-atrial myxoma; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Inflammation
Kidney, disease
(nephritis; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Nerve, neoplasm
(neuroma; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Bone, neoplasm
Sarcoma
(osteosarcoma; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Kidney
(pelvis, tumor; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Anti-infective agents
Anti-inflammatory agents
Antiarthritics
Antidiabetic agents
Antitumor agents
Autoimmune disease
Bladder, neoplasm
Bone, neoplasm
Brain, neoplasm
Cachexia
Diabetes mellitus
Esophagus, neoplasm
Gallbladder, neoplasm
Hepatitis
Human
Immunomodulators
Infection
Inflammation
Kidney, neoplasm
Liver, neoplasm

Lung, neoplasm
Mammary gland, neoplasm
Melanoma
Multiple myeloma
Neuroglia, neoplasm
Osteoporosis
Ovary, neoplasm
Pancreas, neoplasm
Plasma cell leukemia
Prostate gland, neoplasm
Psoriasis
Rheumatoid arthritis
Sepsis
Skin, neoplasm
Stomach, neoplasm
Testis, neoplasm
Thyroid gland, neoplasm
Urinary system, neoplasm
Uterus, neoplasm

(preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

as preventives and/or remedies for diseases)

IT Interleukin 6

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

as preventives and/or remedies for diseases)

IT Kidney, neoplasm

(renal cell carcinoma; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Carcinoma

(renal cell; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Sarcoma

(rhabdomyosarcoma; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Animal tissue, disease

(soft, neoplasm; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Neoplasm

(soft-tissue; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Neoplasm

(solid; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT Globulins, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(γ -, hypergammaglobulinemia; preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors as preventives and/or remedies for diseases)

IT 461404-43-3P 461405-85-6P 461405-86-7P 461405-87-8P 461405-96-9P

461406-03-1P 461406-11-1P 461406-13-3P 461406-15-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

as preventives and/or remedies for diseases)

IT 85594-22-5P 91489-66-6P 114767-55-4P, y 151720-43-3P 174664-71-2P

190911-86-5P 190911-87-6P 191228-04-3P 223466-35-1P 251456-78-7P

408349-39-3P 461404-45-5P 461404-46-6P 461404-47-7P 461404-48-8P

461404-49-9P 461404-50-2P 461404-51-3P 461404-52-4P 461404-53-5P

461404-54-6P	461404-55-7P	461404-56-8P	461404-57-9P	461404-58-0P
461404-59-1P	461404-60-4P	461404-61-5P	461404-62-6P	461404-63-7P
461404-64-8P	461404-65-9P	461404-66-0P	461404-67-1P	461404-68-2P
461404-69-3P	461404-70-6P	461404-71-7P	461404-72-8P	461404-73-9P
461404-74-0P	461404-75-1P	461404-76-2P	461404-77-3P	461404-78-4P
461404-79-5P	461404-80-8P	461404-81-9P	461404-82-0P	461404-83-1P
461404-84-2P	461404-85-3P	461404-86-4P	461404-87-5P	461404-88-6P
461404-89-7P	461404-90-0P	461404-91-1P	461404-92-2P	461404-93-3P
461404-94-4P	461404-95-5P	461404-96-6P	461404-97-7P	461404-98-8P
461404-99-9P	461405-00-5P	461405-01-6P	461405-02-7P	461405-03-8P
461405-04-9P	461405-05-0P	461405-06-1P	461405-07-2P	461405-08-3P
461405-09-4P	461405-10-7P	461405-11-8P	461405-12-9P	461405-13-0P
461405-14-1P	461405-15-2P	461405-16-3P	461405-17-4P	461405-18-5P
461405-19-6P	461405-20-9P	461405-21-0P	461405-22-1P	461405-23-2P
461405-24-3P	461405-25-4P	461405-26-5P	461405-27-6P	461405-28-7P
461405-29-8P	461405-30-1P	461405-31-2P	461405-32-3P	461405-33-4P
461405-34-5P	461405-35-6P	461405-36-7P	461405-37-8P	461405-38-9P
461405-39-0P	461405-40-3P	461405-41-4P	461405-42-5P	461405-43-6P
461405-44-7P	461405-45-8P	461405-46-9P	461405-47-0P	461405-48-1P
461405-49-2P	461405-50-5P	461405-51-6P	461405-52-7P	461405-53-8P
461405-54-9P	461405-55-0P	461405-56-1P	461405-57-2P	461405-58-3P
461405-59-4P	461405-60-7P	461405-61-8P	461405-62-9P	461405-63-0P
461405-64-1P	461405-65-2P	461405-67-4P	461405-68-5P	461405-70-9P
461405-72-1P	461405-74-3P	461405-76-5P	461405-77-6P	
461405-78-7P	461405-79-8P	461405-80-1P	461405-81-2P	461405-82-3P
461405-83-4P	461405-84-5P	461405-88-9P	461405-89-0P	461405-90-3P
461405-97-0P	461406-04-2P	461406-05-3P	461406-06-4P	461406-07-5P
461406-10-0P	461406-17-7P	461406-19-9P	461406-20-2P	461406-21-3P
461406-22-4P				

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

as preventives and/or remedies for diseases)

IT 60-32-2, 6-Aminohexanoic acid 74-88-4, Methyl iodide, reactions 98-59-9, p-Toluenesulfonyl chloride 107-30-2, Methoxymethyl chloride 302-01-2, Hydrazine, reactions 644-08-6 762-04-9, Diethyl phosphonate 1117-97-1 1826-67-1, Vinylmagnesium bromide 2051-62-9, 4-Chlorobiphenyl 5205-39-0 6638-79-5, N-Methoxy-N-methylamine hydrochloride 7664-41-7, Ammonia, reactions 10387-40-3, Potassium thioacetate 14002-51-8, 4-Phenylbenzoyl chloride 18162-48-6, tert-Butyldimethylsilyl chloride 35444-44-1, Methyladipoyl chloride 331230-79-6 461404-44-4

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

as preventives and/or remedies for diseases)

IT 91323-46-5P 251456-79-8P 331230-81-0P 331231-44-8P 461405-91-4P 461405-92-5P 461405-93-6P 461405-94-7P 461405-95-8P 461405-98-1P 461405-99-2P 461406-01-9P 461406-02-0P 461406-08-6P 461406-09-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of N-acylaminoalkanehydroxamic acids as IL-6 production inhibitors

as preventives and/or remedies for diseases)

RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of alcanoic acid derivatives as novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof

AN 2001:185885 CAPLUS
 DN 134:237397
 TI Preparation of alkanolic acid derivatives as novel class of
 cytodifferentiating agents and histone deacetylase inhibitors, and methods
 of use thereof
 IN Richon, Victoria M.; Marks, Paul A.; Rifkind, Richard A.; Breslow, Ronald;
 Belvedere, Sandro; Gershell, Leland; Miller, Thomas A.
 PA Sloan-Kettering Institute for Cancer Research, USA; Trustees of Columbia
 University in the City of New York
 SO PCT Int. Appl., 142 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001018171	A2	20010315	WO 2000-US23232	20000824
	WO 2001018171	A3	20020627		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
CA	2383999	A1	20010315	CA 2000-2383999	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
AU	200069327	A	20010410	AU 2000-69327	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
EP	1231919	A2	20020821	EP 2000-957757	20000824
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
BR	2000014254	A	20020827	BR 2000-14254	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
HU	200202707	A2	20021228	HU 2002-2707	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
US	6511990	B1	20030128	US 2000-645430	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
JP	2003509343	T	20030311	JP 2001-522383	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
NZ	517613	A	20040130	NZ 2000-517613	20000824
				US 1999-152755P	P 19990908
				US 2000-208688P	P 20000601
				WO 2000-US23232	W 20000824
ZA	2002001544	A	20021010	ZA 2002-1544	20020225

US 2004002506	A1	20040101	US 1999-152755P	P	19990908
US 7126001	B2	20061024	US 2002-281875		20021025
			US 1999-152755P	P	19990908
			US 2000-208688P	P	20000601
AU 2005205805	A1	20050929	US 2000-645430	A1	20000824
			AU 2005-205805		20050902
US 2006241129	A1	20061026	AU 2000-69327	A3	20000824
			US 2006-474043		20060622
			US 1999-152755P	P	19990908
			US 2000-208688P	P	20000601
			US 2000-645430	A1	20000824
US 2007010536	A1	20070111	US 2002-281875	A3	20021025
			US 2006-473839		20060622
			US 1999-152755P	P	19990908
			US 2000-208688P	P	20000601
			US 2000-645430	A1	20000824
US 2007010669	A1	20070111	US 2002-281875	A3	20021025
			US 2006-474042		20060622
			US 1999-152755P	P	19990908
			US 2000-208688P	P	20000601
			US 2000-645430	A1	20000824
			US 2002-281875	A1	20021025

OS MARPAT 134:237397

AB The present invention provides the compound having formula
 $R_1NHCOCH(AR_2)(CH_2)_nCONHOH$ (wherein each of R_1 and R_2 is, substituted or unsubstituted, aryl, cycloalkyl, cycloalkylamino, naphtha, pyridineamino, piperidino, tert-Bu, aryloxy, arylalkyloxy, or pyridine group; wherein A is an amido moiety, O, S, NH, or CH₂; and wherein n is an integer from 3 to 8). The present invention also provides a method of selectively inducing growth arrest, terminal differentiation and/or apoptosis of neoplastic cells and thereby inhibiting proliferation of such cells. Moreover, the present invention provides a method of treating a patient having a tumor characterized by proliferation of neoplastic cells. Lastly, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically acceptable amount of the compound above. Thus, N-benzoyl-L- α -aminosuberateanilide, i.e. PhCO-Asu-NHPh, was condensed with tert-butyl diphenylsilyloxyamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH₂Cl₂ at room temperature for 12 h, followed by deprotection with 5% CF₃CO₂H

in

CH₂Cl₂ for 1.5 h to give PhCO-Asu(NHOH)-NHPh (I). I and PhCH₂O₂C-Asu(NHOH)-NHR (R = quinolin-8-yl) showed activity of murine erythroleukemia cell (MEL) differentiation at 200 and 40 nM, resp., and inhibited histone deacetylase (HDAC) with ID₅₀ of 1 and <10 nM, resp.

IT Apoptosis

(neoplastic cells; preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

IT Antitumor agents

Cell differentiation

(preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

IT Fatty acids, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

IT	7661-21-4P	149647-78-9P	149647-93-8P	149648-28-2P	329966-64-5P
	329966-65-6P	329966-66-7P	329966-67-8P	329966-68-9P	329966-69-0P
	329966-70-3P	329966-71-4P	329966-72-5P	329966-73-6P	329966-74-7P
	329966-75-8P	329966-76-9P	329966-77-0P	329966-78-1P	329966-79-2P
	329966-80-5P	329966-81-6P	329966-82-7P	329966-83-8P	329966-84-9P

329966-85-0P 329966-86-1P 329966-87-2P 329966-88-3P
 329966-89-4P 329966-90-7P 329966-91-8P 329966-92-9P 329966-93-0P
 329966-97-4P 329966-98-5P 329967-00-2P 329967-01-3P 329967-02-4P
 329967-03-5P 329967-19-3P 329967-25-1P 329967-32-0P 329967-33-1P
 329967-34-2P 329967-35-3P 329967-36-4P 329967-37-5P 329967-38-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

IT 9076-57-7, Histone deacetylase

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

IT 60-32-2, 6-Aminohexanoic acid 62-53-3, Aniline, reactions 65-85-0, Benzoic acid, reactions 100-61-8, N-Methylaniline, reactions 124-63-0, Methanesulfonyl chloride 407-25-0, Trifluoroacetic anhydride 541-16-2, Di-tert-butyl malonate 578-66-5, 8-Aminoquinoline 591-80-0, 4-Pentenoic acid 813-77-4, Dimethyl chlorophosphate 3946-32-5, Suberic acid monomethyl ester 10387-40-3, Potassium thioacetate 22809-37-6, 6-Bromohexanoyl chloride 49616-61-7, Methyl 6-bromo-2,4-hexadienoate 49645-27-4 103587-51-5, tert-Butyldiphenylsilyloxyamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

IT 6404-29-1P, 6-(tert-Butoxycarbonylamino)hexanoic acid 41624-92-4P

56911-48-9P 58804-62-9P 70374-95-7P 105612-01-9P 174784-94-2P

329966-94-1P 329966-95-2P 329966-96-3P 329966-99-6P 329967-04-6P

329967-05-7P 329967-06-8P 329967-07-9P 329967-08-0P 329967-09-1P

329967-10-4P 329967-11-5P 329967-12-6P 329967-13-7P 329967-14-8P

329967-15-9P 329967-17-1P 329967-18-2P 329967-20-6P 329967-21-7P

329967-22-8P 329967-23-9P 329967-24-0P 329967-26-2P 329967-27-3P

329967-28-4P 329967-29-5P 329967-30-8P 329967-31-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alkanolic acid derivs. as novel class of cytodifferentiating agents and histone deacetylase inhibitors)

L8 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of hydroxamic acids and their use as antitumor agents

AN 1998:430728 CAPLUS

DN 129:148826

TI Preparation of hydroxamic acids and their use as antitumor agents

IN Suzuki, Tsuneji; Tsuchiya, Katsutoshi; Saito, Akiko; Yamashita, Satoshi

PA Mitsui Petrochemical Industries, Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 20 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10182583	A	19980707	JP 1996-345797	19961225
OS	MARPAT 129:148826			JP 1996-345797	19961225
GI					



I

AB Hydroxamic acids I [A = CH₂CH₂, CH:CH, C.tplbond.C; R₁, R₂ = H, NH₂, NO₂, OH, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 (di)alkylamino, C1-4 alkylthio; Z = bond, CO, NHCO, CH₂; the bond A is at meta or para position against the terminal benzene ring] and their pharmacol. acceptable salts are prepared
Amidation of 3-[4-(N,N-dimethyl)amino]benzoylcinnamic acid with H₂NOH.HCl gave the corresponding hydroxamic acid with 14% yield, which at 1 μM induced differentiation of A2780 cell.

IT Cell differentiation

(inducers; preparation of hydroxamic acids as antitumor agents)

IT Antitumor agents

(preparation of hydroxamic acids as antitumor agents)

IT 191228-41-8P 210705-43-4P 210705-44-5P 210705-45-6P
210705-46-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydroxamic acids as antitumor agents)

IT 210705-56-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of hydroxamic acids as antitumor agents)

IT 88-74-4, 2-Nitroaniline 98-88-4, Benzoyl chloride 107-21-1,
1,2-Ethanediol, reactions 619-66-9, Terephthalaldehydic acid 619-84-1
1099-45-2 1122-91-4, 4-Bromobenzaldehyde 3132-99-8,
3-Bromobenzaldehyde 5470-11-1, Hydroxylamine hydrochloride 13026-23-8,
4-Phenylcinnamic acid

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of hydroxamic acids as antitumor agents)

IT 10602-01-4P, 2-(4-Bromophenyl)-1,3-dioxolane 17789-14-9P,
2-(3-Bromophenyl)-1,3-dioxolane 71856-95-6P, 3-Benzoylbenzaldehyde
96251-93-3P 209784-99-6P 210705-47-8P 210705-48-9P 210705-49-0P
210705-50-3P 210705-51-4P 210705-52-5P 210705-53-6P 210705-54-7P
210705-55-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of hydroxamic acids as antitumor agents)

L8 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of arylhydroxamates and related compounds as potent inducers of terminal differentiation.

AN 1998:8261 CAPLUS

DN 128:75197

TI Preparation of arylhydroxamates and related compounds as potent inducers of terminal differentiation.

IN Breslow, Ronald; Marks, Paul A.; Rifkind, Richard A.

PA Sloan-Kettering Institute for Cancer Research, USA

SO U.S., 24 pp., Cont.-in-part of U.S. 5,369,108.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5700811	A	19971223	US 1994-246363	19940519

US 5369108	A	19941129	US 1991-771760	A2	19911004
AT 183185	T	19990815	US 1991-771760		19911004
			AT 1992-922033		19921005
ES 2134815	T3	19991016	US 1991-771760	A	19911004
			ES 1992-922033		19921005
JP 2003226680	A	20030812	US 1991-771760	A	19911004
			JP 2002-337049		19921005
			US 1991-771760	A	19911004
US 5932616	A	19990803	JP 1993-507109	A3	19921005
			US 1994-222685		19940404
CA 2190765	A1	19951130	US 1991-771760	A3	19911004
			CA 1995-2190765		19950519
WO 9531977	A1	19951130	US 1994-246363	A	19940519
W: AU, CA, JP, MX			WO 1995-US6554		19950519
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
AU 9526474	A	19951218	US 1994-246363	A	19940519
AU 692561	B2	19980611	AU 1995-26474		19950519
			US 1994-246363	A	19940519
EP 760657	A1	19970312	WO 1995-US6554	W	19950519
EP 760657	B1	20031112	EP 1995-921378		19950519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			US 1994-246363	A	19940519
AT 253906	T	20031115	WO 1995-US6554	W	19950519
			AT 1995-921378		19950519
			US 1994-246363	A	19940519
ES 2210293	T3	20040701	WO 1995-US6554	W	19950519
			ES 1995-921378		19950519
AU 9662063	A	19961017	US 1994-246363	A	19940519
AU 708115	B2	19990729	AU 1996-62063		19960813
			US 1991-771760	A	19911004
US 6087367	A	20000711	US 1999-314195		19990518
			US 1991-771760	A3	19911004
			US 1994-222685	A1	19940404
US 38506	E1	20040420	US 2001-4411		20011102
			US 1991-771760	A5	19911004

PATENT FAMILY INFORMATION:

FAN 1993:538765

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307148	A1	19930415	WO 1992-US8454	19921005
	W: AU, CA, FI, HU, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5369108	A	19941129	US 1991-771760	A 19911004
	AU 9228703	A	19930503	US 1991-771760	19911004
	AU 668696	B2	19960516	AU 1992-28703	19921005
				US 1991-771760	A 19911004
	EP 642509	A1	19950315	WO 1992-US8454	A 19921005
	EP 642509	B1	19990811	EP 1992-922033	19921005
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
	JP 07502494	T	19950316	US 1991-771760	A 19911004
	JP 3432823	B2	20030804	WO 1992-US8454	W 19921005
				JP 1993-507109	19921005
				US 1991-771760	A 19911004
	HU 67421	A2	19950428	WO 1992-US8454	W 19921005
	HU 225497	B1	20070129	HU 1994-959	19921005

RU 2128643	C1	19990410	US 1991-771760	A	19911004
			WO 1992-US8454	W	19921005
			RU 1994-21660		19921005
			US 1991-771760	A	19911004
AT 183185	T	19990815	WO 1992-US8454	W	19921005
			AT 1992-922033		19921005
ES 2134815	T3	19991016	US 1991-771760	A	19911004
			ES 1992-922033		19921005
JP 2003226680	A	20030812	US 1991-771760	A	19911004
			JP 2002-337049		19921005
			US 1991-771760	A	19911004
CA 2120619	C	20061121	JP 1993-507109	A3	19921005
			CA 1992-2120619		19921005
			US 1991-771760	A	19911004
NO 9401166	A	19940530	WO 1992-US8454	W	19921005
			NO 1994-1166		19940329
			US 1991-771760	A	19911004
FI 9401537	A	19940531	WO 1992-US8454	A	19921005
			FI 1994-1537		19940331
			US 1991-771760	A	19911004
US 5932616	A	19990803	WO 1992-US8454	W	19921005
			US 1994-222685		19940404
AU 9662063	A	19961017	US 1991-771760	A3	19911004
AU 708115	B2	19990729	AU 1996-62063		19960813
US 6087367	A	20000711	US 1991-771760	A	19911004
			US 1999-314195		19990518
			US 1991-771760	A3	19911004
			US 1994-222685	A1	19940404
US 38506	E1	20040420	US 2001-4411		20011102
			US 1991-771760	A5	19911004
FAN 1996:181546					
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
-----	-----	-----	-----	-----	
PI WO 9531977	A1	19951130	WO 1995-US6554		19950519
W: AU, CA, JP, MX					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
US 5700811	A	19971223	US 1994-246363	A	19940519
			US 1994-246363		19940519
			US 1991-771760	A2	19911004
AU 9526474	A	19951218	AU 1995-26474		19950519
AU 692561	B2	19980611			
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
EP 760657	A1	19970312	EP 1995-921378		19950519
EP 760657	B1	20031112			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
AT 253906	T	20031115	AT 1995-921378		19950519
			US 1994-246363	A	19940519
			WO 1995-US6554	W	19950519
OS MARPAT 128:75197					
AB R1CO(CH2)nCOR2 [R1 = R2 = (substituted) arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amino, thiazoleamino; or R1 ≠ R2 and R1 = NR3R4; R3, R4 = H, OH, (substituted) alkyl, alkenyl, cycloalkyl, aryl, alkoxy, aryloxy, aralkoxy, pyridyl; R3R4N = piperidino; n = 4-8; R2 = hydroxylamino, OH, amino, alkoxy], and related compds., were prepared Thus, 3-HONHCOC6H4CH:CHCONHOH (prepared by reaction of H2NOSiMe3 with the corresponding diacid dichloride) induced terminal differentiation with an optimal concentrate of 4 μM with 73% benzidine reactive cells.					
IT Cell differentiation					
(inducers of terminal differentiation of neoplastic cells; preparation of					

arylhydroxamates and related compds. as potent inducers of terminal differentiation)

IT Antitumor agents

(preparation of aarylhydroxamates and related compds. as potent inducers of terminal differentiation)

IT 5502-67-0P 39642-93-8P 149647-78-9P 149647-81-4P 149647-82-5P
149647-83-6P 149647-85-8P 149647-86-9P 149647-87-0P 149647-88-1P
149647-89-2P 149647-90-5P 149647-91-6P 149647-96-1P 149647-97-2P
149647-98-3P 149648-24-8P 149648-29-3P 149648-30-6P
149648-31-7P 149648-32-8P 149648-39-5P 149648-46-4P 149648-49-7P
149648-50-0P 149648-52-2P 149648-54-4P 149648-56-6P 149648-57-7P
149648-68-0P 149648-69-1P 174664-65-4P 174664-66-5P 174664-68-7P
174664-70-1P 174664-71-2P 200800-88-0P 200800-89-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aarylhydroxamates and related compds. as potent inducers of terminal differentiation)

IT 60-32-2, 6-Aminocaproic acid 62-53-3, Benzenamine, reactions 98-88-4, Benzoyl chloride 100-20-9, 1,4-Benzenedicarbonyl dichloride 504-24-5, 4-Aminopyridine 622-33-3, O-Benzylhydroxylamine 929-17-9, 7-Aminoheptanoic acid 2687-43-6, O-Benzylhydroxylamine hydrochloride 3946-32-5, Suberic acid monomethyl ester 10027-07-3, Suberoyl chloride 16323-43-6, 1,4-Phenylenediacrylic acid 22737-36-6, O-Trimethylsilylhydroxylamine

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aarylhydroxamates and related compds. as potent inducers of terminal differentiation)

IT 1149-15-1P, 7-(Benzoylamino)heptanoic acid 94136-35-3P, N-Benzyloxy-6-bromohexanamide 99647-94-6P 149648-51-1P, N-Benzyloxy-6-cyanohexanamide 200800-91-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aarylhydroxamates and related compds. as potent inducers of terminal differentiation)

L8 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of alkanedicarboxylic acid amides as novel potent inducers of terminal differentiation of neoplastic cell

AN 1996:181546 CAPLUS

DN 124:260602

TI Preparation of alkanedicarboxylic acid amides as novel potent inducers of terminal differentiation of neoplastic cell

IN Breslow, Ronald; Marks, Paul A.; Rifkind, Richard A.

PA Sloan-Kettering Institute for Cancer Research, USA; Trustees of Columbia University in the City of New York

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9531977	A1	19951130	WO 1995-US6554	19950519
W: AU, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5700811	A	19971223	US 1994-246363	A 19940519
			US 1994-246363	19940519
			US 1991-771760	A2 19911004
AU 9526474	A	19951218	AU 1995-26474	19950519
AU 692561	B2	19980611		
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519

EP 760657	A1	19970312	EP 1995-921378	19950519
EP 760657	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
AT 253906	T	20031115	AT 1995-921378	19950519
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519

PATENT FAMILY INFORMATION:

FAN 1993:538765

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307148	A1	19930415	WO 1992-US8454	19921005
	W: AU, CA, FI, HU, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5369108	A	19941129	US 1991-771760	A 19911004
	AU 9228703	A	19930503	US 1991-771760	19911004
	AU 668696	B2	19960516	AU 1992-28703	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	EP 642509	A1	19950315	EP 1992-922033	19921005
	EP 642509	B1	19990811		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	JP 07502494	T	19950316	JP 1993-507109	19921005
	JP 3432823	B2	20030804		
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	HU 67421	A2	19950428	HU 1994-959	19921005
	HU 225497	B1	20070129		
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	RU 2128643	C1	19990410	RU 1994-21660	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004
				JP 1993-507109	A3 19921005
	CA 2120619	C	20061121	CA 1992-2120619	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	NO 9401166	A	19940530	NO 1994-1166	19940329
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	FI 9401537	A	19940531	FI 1994-1537	19940331
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	US 5932616	A	19990803	US 1994-222685	19940404
				US 1991-771760	A3 19911004
	AU 9662063	A	19961017	AU 1996-62063	19960813
	AU 708115	B2	19990729		
				US 1991-771760	A 19911004
	US 6087367	A	20000711	US 1999-314195	19990518
				US 1991-771760	A3 19911004
				US 1994-222685	A1 19940404
	US 38506	E1	20040420	US 2001-4411	20011102
				US 1991-771760	A5 19911004

FAN	1998:8261				
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5700811	A	19971223	US 1994-246363	19940519
				US 1991-771760	A2 19911004
	US 5369108	A	19941129	US 1991-771760	19911004
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004
	US 5932616	A	19990803	JP 1993-507109	A3 19921005
				US 1994-222685	19940404
	CA 2190765	A1	19951130	US 1991-771760	A3 19911004
				CA 1995-2190765	19950519
	WO 9531977	A1	19951130	US 1994-246363	A 19940519
	W: AU, CA, JP, MX			WO 1995-US6554	19950519
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9526474	A	19951218	US 1994-246363	A 19940519
	AU 692561	B2	19980611	AU 1995-26474	19950519
				US 1994-246363	A 19940519
	EP 760657	A1	19970312	WO 1995-US6554	W 19950519
	EP 760657	B1	20031112	EP 1995-921378	19950519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	AT 253906	T	20031115	AT 1995-921378	19950519
				US 1994-246363	A 19940519
				WO 1995-US6554	W 19950519
	ES 2210293	T3	20040701	ES 1995-921378	19950519
				US 1994-246363	A 19940519
	AU 9662063	A	19961017	AU 1996-62063	19960813
	AU 708115	B2	19990729		
				US 1991-771760	A 19911004
	US 6087367	A	20000711	US 1999-314195	19990518
				US 1991-771760	A3 19911004
				US 1994-222685	A1 19940404
	US 38506	E1	20040420	US 2001-4411	20011102
				US 1991-771760	A5 19911004

OS MARPAT 124:260602

AB Alkanedicarboxylic acid amides $R_1CO(CH_2)_nCOR_2$ [I; wherein each of R_1 and R_2 are independently the same or different from each other; R_1 and R_2 are the same, each is a substituted or unsubstituted arylamino, cycloalkylamino, pyridineamino, piperidino, 9-purine-6-amine, or thiazoleamino group; when R_1 and R_2 are different, $R_1 = R_3-NR_4$, wherein each of R_3 and R_4 are independently the same as or different from each other and are H, HO, (un)substituted, branched or unbranched alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, or pyridine group, or R_3 and R_4 bond together to form a piperidine group and R_2 is a hydroxylamino, HO, NH_2 , alkylamino, dialkylamino or alkyloxy group; n = an integer from about 4-8], which inhibit proliferation of such cells and are useful for treating a patient having a tumor characterized by proliferation of neoplastic cells, are prepared Thus, chlorination of suberic acid monomethyl ester with oxalyl chloride benzene containing DMF to suberoyl chloride followed by condensation with O-benzylhydroxylamine in pyridine/ $CHCl_3$ at room temperature overnight gave 89% $PhCH_2ONHCO(CH_2)_6CO_2Me$. Hydrogenolysis of the latter compound in the presence of 5% Pd-C under .apprx.50 psi H atmospheric to $HONHC(O)(CH_2)_6CO_2Me$ followed by saponification with KOH in

aqueous MeOH under reflux for 2 h and acidification with concentrated HCl gave HONHC(O)(CH₂)₆CO₂H. PhONHC(O)(CH₂)₆C(O)NHOH at 3 μM in vitro induced the differentiation of MELC cells and HL-60 human leukemia cells by 21 and 65%, resp.

IT Cell differentiation

Neoplasm

Neoplasm inhibitors

(preparation of alkanedicarboxylic acid amides as inducers of terminal differentiation of neoplastic cell and as anticancer agents)

IT	5502-67-0P	20073-81-8P	39642-93-8P	56384-27-1P	136268-94-5P
	149647-77-8P	149647-78-9P	149647-79-0P	149647-80-3P	149647-81-4P
	149647-82-5P	149647-83-6P	149647-84-7P	149647-85-8P	149647-86-9P
	149647-87-0P	149647-89-2P	149647-90-5P	149647-91-6P	149647-92-7P
	149647-93-8P	149647-94-9P	149647-95-0P	149647-96-1P	149647-97-2P
	149647-98-3P	149647-99-4P	149648-00-0P	149648-01-1P	149648-02-2P
	149648-03-3P	149648-04-4P	149648-05-5P	149648-06-6P	149648-07-7P
	149648-08-8P	149648-09-9P	149648-10-2P	149648-11-3P	149648-12-4P
	149648-13-5P	149648-14-6P	149648-15-7P	149648-16-8P	149648-17-9P
	149648-18-0P	149648-19-1P	149648-20-4P	149648-21-5P	149648-22-6P
	149648-23-7P	149648-24-8P	149648-25-9P	149648-26-0P	149648-27-1P
	149648-28-2P	149648-29-3P	149648-30-6P	149648-31-7P	
	149648-32-8P	149648-33-9P	149648-34-0P	149648-35-1P	149648-36-2P
	149648-37-3P	149648-38-4P	149648-39-5P	149648-40-8P	149648-41-9P
	149648-42-0P	149648-43-1P	149648-44-2P	149648-45-3P	149648-46-4P
	149648-47-5P	149648-48-6P	149648-49-7P	149648-50-0P	149648-52-2P
	149648-54-4P	149648-56-6P	149648-57-7P	149648-60-2P	149648-65-7P
	149648-68-0P	149648-69-1P	174664-65-4P	174664-66-5P	174664-67-6P
	174664-68-7P	174664-69-8P	174664-70-1P	174664-71-2P	174664-72-3P
	174664-73-4P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of alkanedicarboxylic acid amides as inducers of terminal differentiation of neoplastic cell and as anticancer agents)

IT	60-32-2, 6-Aminocaproic acid	62-53-3, Aniline, reactions	98-88-4, Benzoyl chloride	100-20-9, Terephthaloyl chloride	100-61-8, N-Methylaniline, reactions	143-33-9, Sodium cyanide	504-24-5, 4-Aminopyridine	506-59-2, Dimethylamine hydrochloride	622-33-3, O-Benzylhydroxylamine	929-17-9, 7-Aminoheptanoic acid	2687-43-6, O-Benzylhydroxylamine hydrochloride	2909-38-8, m-Chlorophenyl isocyanate	3946-32-5, Suberic acid monomethyl ester	5470-11-1, Hydroxylamine hydrochloride	16323-43-6, 1,4-Phenylenediacrylic acid	22737-36-6, O-(Trimethylsilyl)hydroxylamine	22809-37-6, 6-Bromohexanoyl chloride	149648-51-1, N-Benzyloxy-6-cyanoheptanamide
----	------------------------------	-----------------------------	---------------------------	----------------------------------	--------------------------------------	--------------------------	---------------------------	---------------------------------------	---------------------------------	---------------------------------	--	--------------------------------------	--	--	---	---	--------------------------------------	---

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of alkanedicarboxylic acid amides as inducers of terminal differentiation of neoplastic cell and as anticancer agents)

IT	1149-15-1P, 7-Benzamidoheptanoic acid	10027-07-3P, Suberoyl chloride	94136-35-3P, N-Benzyloxy-6-bromohexanamide	149647-88-1P	174664-74-5P
----	---------------------------------------	--------------------------------	--	--------------	--------------

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of alkanedicarboxylic acid amides as inducers of terminal differentiation of neoplastic cell and as anticancer agents)

L8 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN

TI Nucleophilic reactions of N-hydroxy-, methoxy-, 2,3-epoxypropoxy-phthalimides

AN 1995:237245 CAPLUS


DN 122:239480

TI Nucleophilic reactions of N-hydroxy-, methoxy-, 2,3-epoxypropoxy-phthalimides

AU Ranadive, V. B.; Khadilkar, B. M.; Samant, S. D.

CS Org. Chem. Res. Lab., Univ. Dep. Chem. Technol., Bombay, 400 019, India

SO Indian Journal of Chemistry, Section B: Organic Chemistry Including
Medicinal Chemistry (1994), 33B(12), 1175-7
CODEN: IJSBDB; ISSN: 0376-4699
PB Publications & Information Directorate, CSIR
DT Journal
LA English
GI



- AB Reaction of N-hydroxyphthalimide (I, R = OH) with equivalent amts. of aliphatic and aromatic primary amines gives the N-substituted phthalimides I (R = PhCH₂, CH₂CH₂Ph, Ph, CMe₃, 4-Me₆H₄, etc.), while with excess of these amines it gives the diamides of phthalic acid, 1,2-(RNHCO)₂C₆H₄ [R = CH₂Ph, CH₂CH₂Ph, CHMe₂, CH₂CH₂Me, CH₂(CH₂)₂Me]. The reaction of I (R = OH) with t-Bu amine gives only the Bu monoamide of phthaloylhydroxamic acid. N-methoxyphthalimide reacts in the same manner. I (R = OH) does not condense with epichlorohydrin, but condenses with epibromohydrin to give N-(2,3-epoxypropoxy)phthalimide (II) which on reaction with equivalent amts. of aliphatic primary amines gives the N-substituted phthalimides and with excess of the amines it gives the diamides of phthalic acid. The reaction of II with aromatic primary amines gives only the N-arylphthalimides. Secondary amines do not react with II.
- IT 62-53-3, Aniline, reactions 64-04-0, 2-Phenyl-1-ethylamine 75-31-0, Isopropylamine, reactions 75-64-9, tert-Butylamine, reactions 85-44-9, Phthalic anhydride 95-53-4, 2-Methylaniline, reactions 100-46-9, Benzylamine, reactions 106-49-0, 4-Methylaniline, reactions 107-10-8, 1-Propanamine, reactions 109-73-9, 1-Butanamine, reactions 3132-64-7, Epibromohydrin
RL: RCT (Reactant); RACT (Reactant or reagent)
(nucleophilic reactions of N-hydroxy-, methoxy-, and (epoxypropoxy)-phthalimides)
- IT 524-38-9P, N-Hydroxyphthalimide 1914-20-1P, N-Methoxyphthalimide 58288-28-1P, 1H-Isoindole-1,3(2H)-dione, 2-hydroxy-, potassium salt 80041-90-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(nucleophilic reactions of N-hydroxy-, methoxy-, and (epoxypropoxy)-phthalimides)
- IT 304-17-6P, N-Isopropylphthalimide 520-03-6P, N-Phenylphthalimide 1515-72-6P, N-Butylphthalimide 2141-99-3P, N-tert-Butylphthalimide 2142-01-0P, N-Benzylphthalimide 2142-03-2P, N-(p-Tolyl)phthalimide 2464-33-7P, N-(o-Tolyl)phthalimide 5323-50-2P, N-Propylphthalimide 7501-05-5P, N-Phenethylphthalimide 19532-95-7P 19532-96-8P 38228-97-6P 38228-99-8P 38229-00-4P 162316-52-1P 162316-53-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(nucleophilic reactions of N-hydroxy-, methoxy-, and (epoxypropoxy)-phthalimides)
- L8 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2007 ACS on STN
TI Alkanedioic acid derivatives, novel potent inducers of terminal differentiation and methods of use thereof

AN 1993:538765 CAPLUS
 DN 119:138765
 TI Alkanedioic acid derivatives, novel potent inducers of terminal
 differentiation and methods of use thereof
 IN Breslow, Ronald; Marks, Paul A.; Rifkind, Richard A.; Jursic, Branko
 PA Sloan-Kettering Institute for Cancer Research, USA; Columbia University
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9307148	A1	19930415	WO 1992-US8454	19921005
	W: AU, CA, FI, HU, JP, KR, NO, RU				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE				
	US 5369108	A	19941129	US 1991-771760	A 19911004
	AU 9228703	A	19930503	US 1991-771760	19911004
	AU 668696	B2	19960516	AU 1992-28703	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	EP 642509	A1	19950315	EP 1992-922033	19921005
	EP 642509	B1	19990811		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, SE				
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	JP 07502494	T	19950316	JP 1993-507109	19921005
	JP 3432823	B2	20030804		
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	HU 67421	A2	19950428	HU 1994-959	19921005
	HU 225497	B1	20070129		
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	RU 2128643	C1	19990410	RU 1994-21660	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	AT 183185	T	19990815	AT 1992-922033	19921005
				US 1991-771760	A 19911004
	ES 2134815	T3	19991016	ES 1992-922033	19921005
				US 1991-771760	A 19911004
	JP 2003226680	A	20030812	JP 2002-337049	19921005
				US 1991-771760	A 19911004
				JP 1993-507109	A3 19921005
	CA 2120619	C	20061121	CA 1992-2120619	19921005
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	NO 9401166	A	19940530	NO 1994-1166	19940329
				US 1991-771760	A 19911004
				WO 1992-US8454	A 19921005
	FI 9401537	A	19940531	FI 1994-1537	19940331
				US 1991-771760	A 19911004
				WO 1992-US8454	W 19921005
	US 5932616	A	19990803	US 1994-222685	19940404
				US 1991-771760	A3 19911004
	AU 9662063	A	19961017	AU 1996-62063	19960813
	AU 708115	B2	19990729		
				US 1991-771760	A 19911004
	US 6087367	A	20000711	US 1999-314195	19990518
				US 1991-771760	A3 19911004
				US 1994-222685	A1 19940404
	US 38506	E1	20040420	US 2001-4411	20011102

US 1991-771760

A5 19911004

PATENT FAMILY INFORMATION:

FAN 1996:181546

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9531977	A1	19951130	WO 1995-US6554	19950519
W: AU, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5700811	A	19971223	US 1994-246363	A 19940519
			US 1994-246363	19940519
			US 1991-771760	A2 19911004
AU 9526474	A	19951218	AU 1995-26474	19950519
AU 692561	B2	19980611		
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
EP 760657	A1	19970312	EP 1995-921378	19950519
EP 760657	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
AT 253906	T	20031115	AT 1995-921378	19950519
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519

FAN 1998:8261

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5700811	A	19971223	US 1994-246363	19940519
			US 1991-771760	A2 19911004
US 5369108	A	19941129	US 1991-771760	19911004
AT 183185	T	19990815	AT 1992-922033	19921005
			US 1991-771760	A 19911004
ES 2134815	T3	19991016	ES 1992-922033	19921005
			US 1991-771760	A 19911004
JP 2003226680	A	20030812	JP 2002-337049	19921005
			US 1991-771760	A 19911004
			JP 1993-507109	A3 19921005
US 5932616	A	19990803	US 1994-222685	19940404
			US 1991-771760	A3 19911004
CA 2190765	A1	19951130	CA 1995-2190765	19950519
			US 1994-246363	A 19940519
WO 9531977	A1	19951130	WO 1995-US6554	19950519
W: AU, CA, JP, MX				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
			US 1994-246363	A 19940519
AU 9526474	A	19951218	AU 1995-26474	19950519
AU 692561	B2	19980611		
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
EP 760657	A1	19970312	EP 1995-921378	19950519
EP 760657	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
AT 253906	T	20031115	AT 1995-921378	19950519
			US 1994-246363	A 19940519
			WO 1995-US6554	W 19950519
ES 2210293	T3	20040701	ES 1995-921378	19950519
			US 1994-246363	A 19940519
AU 9662063	A	19961017	AU 1996-62063	19960813
AU 708115	B2	19990729		
			US 1991-771760	A 19911004
US 6087367	A	20000711	US 1999-314195	19990518
			US 1991-771760	A3 19911004

US 38506	E1	20040420	US 1994-222685	A1 19940404
			US 2001-4411	20011102
			US 1991-771760	A5 19911004

OS MARPAT 119:138765

AB Alkylene bisamides and monoamides $R_1CO(CH_2)_nCOR_2$ [$R_1 = R_2 =$ (un)substituted arylamino, cycloalkylamino, pyridylamino, piperidino, 9-purine-6-amino, thiazolylamino; $R_1 = R_3R_4N$, where $R_3 = H, OH$, (un)substituted alkyl, alkenyl, cycloalkyl, aryl, alkyloxy, aryloxy, arylalkyloxy, pyridyl or $R_3R_4N =$ piperidino; $R_2 =$ hydroxyamino, hydroxy, amino, alkylamino, dialkylamino, alkyloxy; $n = 4-8$] were prepared for selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting their proliferation (data tabulated). Thus, a pyridine solution of H_2NOCH_2Ph , H_2NOMe , and suberoyl chloride was stirred overnight at room temperature. The product was treated with 10% HCl in $HCCl_3-MeOH$ and hydrogenated over 5% Pd/C to give $HONHCO(CH_2)_6CONHOMe$.

IT 3946-32-5, Suberic acid monomethyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)
(acid chlorination of)

IT 100-61-8, N-Methylaniline, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with diacid chlorides)

IT 67-62-9, O-Methylhydroxylamine 108-91-8, Cyclohexylamine, reactions

110-89-4, Piperidine, reactions 622-33-3, O-Benzylhydroxylamine

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with suberic acid derivative)

IT 96-50-4, 2-Thiazolamine 455-14-1 462-08-8, 3-Aminopyridine 3544-25-0

6274-22-2, 4-Amino-N-methylbenzamide 26071-05-6, 4-Amino-N-hydroxybenzamide

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with suberic chloride)

IT 110-70-3, N,N'-Dimethylethylenediamine

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with suberic chloride monomethyl ester)

IT 372-39-4, 3,5-Difluoroaniline 504-24-5, 4-Pyridinamine 782-45-6

873-74-5 1885-29-6 2237-30-1 22737-36-6, O-(Trimethylsilyl)hydroxylamine

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with suberoyl chloride)

IT 60-32-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(acylation of, with terephthaloyl chloride)

IT 100-20-9, 1,4-Benzenedicarbonyl dichloride 10027-07-3, Suberoyl chloride 23713-85-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of)

IT 111-19-3, Decanedioic dichloride 111-50-2, Hexanedioic dichloride

123-98-8, Nonanedioic dichloride 142-79-0, Heptanedioic dichloride

RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with aniline or methylaniline)

IT 22809-37-6, 6-Bromohexanoyl chloride 78582-38-4, Heptanedioic chloride benzyl ester

RL: RCT (Reactant); RACT (Reactant or reagent)
(amidation of, with benzylhydroxylamine)

IT 41624-92-4P, Suberic chloride methyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amidation of)

IT 94136-35-3P, N-Benzoyloxy-6-bromohexanoyl amide

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyanation of)

IT 149648-49-7P 149648-51-1P, N-Benzoyloxy-6-cyanohehexanoylamide

149648-53-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and debenzylation of)

IT 5502-67-0P 149647-78-9P 149647-81-4P 149647-82-5P 149647-83-6P
149647-85-8P 149647-86-9P 149647-88-1P 149647-89-2P 149647-90-5P
149647-91-6P 149647-96-1P 149647-97-2P 149647-98-3P 149648-24-8P
149648-29-3P 149648-30-6P 149648-39-5P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and terminal differentiation inducer activity of)

IT 2409-13-4P 39642-93-8P 149648-50-0P 149648-52-2P 149648-54-4P
149648-55-5P 149648-56-6P 149648-57-7P 149648-58-8P 149648-59-9P
149648-60-2P 149648-61-3P 149648-62-4P 149648-63-5P 149648-64-6P
149648-65-7P 149648-66-8P 149648-67-9P 149648-68-0P 149648-69-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

IT 56384-27-1 136268-94-5 149647-77-8 149647-79-0 149647-80-3
149647-84-7 149647-87-0 149647-92-7 149647-93-8 149647-94-9
149647-95-0 149647-99-4 149648-00-0 149648-01-1 149648-02-2
149648-03-3 149648-04-4 149648-05-5 149648-06-6 149648-07-7
149648-08-8 149648-09-9 149648-10-2 149648-11-3 149648-12-4
149648-13-5 149648-14-6 149648-15-7 149648-16-8 149648-17-9
149648-18-0 149648-19-1 149648-20-4 149648-21-5 149648-22-6
149648-23-7 149648-25-9 149648-26-0 149648-27-1 149648-28-2
149648-31-7 149648-32-8 149648-33-9 149648-34-0 149648-35-1
149648-36-2 149648-37-3 149648-38-4 149648-40-8 149648-41-9
149648-42-0 149648-43-1 149648-44-2 149648-45-3 149648-46-4
149648-47-5 149648-48-6

RL: RCT (Reactant); RACT (Reactant or reagent)

(terminal differentiation inducer activity of)

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	65.32	320.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-9.36	-10.92

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 11:29:34 ON 20 FEB 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 11:55:39 ON 20 FEB 2007
FILE 'CAPLUS' ENTERED AT 11:55:39 ON 20 FEB 2007
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	65.32	320.25
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

CA SUBSCRIBER PRICE	ENTRY -9.36	SESSION -10.92
=> file reg		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	66.73	321.66
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.36	-10.92

FILE 'REGISTRY' ENTERED AT 11:57:25 ON 20 FEB 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6
 DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Documents and Settings\PZucker\My Documents\Examination Auxillary
 files\10811332\10811332sulponmide first stab.str



```

chain nodes :
1 2 3 4 5 6 9 10 11 12 24 25 32 33 40 41
ring nodes :
18 19 20 21 22 23 26 27 28 29 30 31 34 35 36 37 38 39
chain bonds :
1-2 2-4 3-4 4-5 5-6 9-10 11-12 19-24 24-25 27-32 32-33 35-40 40-41
ring bonds :
18-19 18-23 19-20 20-21 21-22 22-23 26-27 26-31 27-28 28-29 29-30 30-31
34-35 34-39 35-36 36-37 37-38 38-39
exact/norm bonds :
1-2 3-4 4-5 9-10 11-12 19-24 24-25 27-32 32-33 35-40 40-41
exact bonds :
2-4 5-6
normalized bonds :
18-19 18-23 19-20 20-21 21-22 22-23 26-27 26-31 27-28 28-29 29-30 30-31
34-35 34-39 35-36 36-37 37-38 38-39

```

G1:[*1-*2],[*3-*4]

G2:[*5],[*6],[*7]

Match level :

```

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 9:CLASS 10:CLASS 11:CLASS
12:CLASS 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 24:CLASS 25:Atom
26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom 32:CLASS 33:Atom 34:Atom
35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:CLASS 41:Atom

```

L9 STRUCTURE UPLOADED

=> d 19

L9 HAS NO ANSWERS

L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> seaerch 19 sss sam

COMBINATION OF STRUCTURE AND TEXT TERMS NOT VALID

The query entered contains both search terms created by structure-building or screen commands and text search terms. L#s created via the STRUCTURE or SCREEN commands must be searched in the structures files separately from text terms or profiles. The L# answer sets from structure searches can be used in crossover searches and can be combined with text terms.

=>

=> search 19 sss sam

SAMPLE SEARCH INITIATED 11:58:21 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5037 TO ITERATE

39.7% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
PROJECTED ITERATIONS: 96485 TO 104995
PROJECTED ANSWERS: 39 TO 463


L10 5 SEA SSS SAM L9

=> d scan

L10 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Propenamide, 3-[4-[(2-dibenzofuranylsulfonyl)amino]phenyl]-N-hydroxy-
(9CI)

MF C21 H16 N2 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5


L10 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-hydroxy-3-[3-[[[4-(trifluoromethyl)phenyl]amino]sulfonyl]
phenyl]-, (2E)- (9CI)
MF C16 H13 F3 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L10 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-hydroxy-3-[4-[(2-thienylsulfonyl)amino]phenyl]- (9CI)
MF C13 H12 N2 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L10 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, 3-[4-[[[4-chlorophenyl]sulfonyl]amino]phenyl]-N-hydroxy-,
(2E)- (9CI)
MF C15 H13 Cl N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 5 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, N-hydroxy-3-methyl-2-[[[5-(2-pyridinyl)-2-thienyl]sulfonyl]amino]- (9CI)
MF C17 H15 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
1.35	323.01

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-10.92

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:59:30 ON 20 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Feb 2007 VOL 146 ISS 9

FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l10


L11 7 L10

=> d l11 1-7 ti fbib abs

L11 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN

TI Novel sulfonamide derivatives as inhibitors of histone deacetylase
 AN 2005:842556 CAPLUS
 DN 143:359422
 TI Novel sulfonamide derivatives as inhibitors of histone deacetylase
 AU Finn, Paul W.; Bandara, Morwena; Butcher, Chris; Finn, Angela;
 Hollinshead, Ruth; Khan, Nagma; Law, Norman; Murthy, Sreenivasa; Romero,
 Rosario; Watkins, Clare; Andrianov, Victor; Bokaldere, Rasma M.; Dikovska,
 Klara; Gailite, Vija; Loza, Einars; Piskunova, Irina; Starchenkov, Igor;
 Vorona, Maxim; Kalvinsh, Ivars
 CS TopoTarget UK Ltd., Abingdon, OX14 4RY, UK
 SO Helvetica Chimica Acta (2005), 88(7), 1630-1657
 CODEN: HCACAV; ISSN: 0018-019X
 PB Verlag Helvetica Chimica Acta
 DT Journal
 LA English
 OS CASREACT 143:359422
 AB Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel
 approach to the treatment of cancer. A series of novel sulfonamide
 derivs. were synthesized and evaluated for their ability to inhibit human
 HDAC. Compds. were identified which are potent enzyme inhibitors, with
 IC50 values in the low nanomolar range against enzyme obtained from HeLa
 cell exts., and with antiproliferative effects in cell culture. Extensive
 characterization of the structure-activity relationships of this series
 identified key requirements for activity. These include the direction of
 the sulfonamide bond and substitution patterns on the central Ph ring.
 The alkyl spacer between the aromatic head group and the sulfonamide
 functionality also influenced the HDAC inhibitory activity. One of these
 compds., mll.1, also designated PXD101, has entered clin. trials for solid
 tumors and haematol. malignancies.
 RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Polymer-assisted, multi-step solution phase synthesis and biological
 screening of histone deacetylase inhibitors
 AN 2004:231325 CAPLUS
 DN 140:406594
 TI Polymer-assisted, multi-step solution phase synthesis and biological
 screening of histone deacetylase inhibitors
 AU Bapna, Akanksha; Vickerstaffe, Emma; Warrington, Brian H.; Ladlow, Mark;
 Fan, Tai-Ping D.; Ley, Steven V.
 CS Department of Pharmacology, University of Cambridge, Cambridge, CB2 1QJ,
 UK
 SO Organic & Biomolecular Chemistry (2004), 2(4), 611-620
 CODEN: OBCRAK; ISSN: 1477-0520
 PB Royal Society of Chemistry
 DT Journal
 LA English
 OS CASREACT 140:406594
 GI



AB The polymer-assisted solution phase synthesis (PASP) of an array of
 hydroxamic acids I [R1 = 4-MeC6H4, 3,4-(MeO)2C6H3, 2-thienyl, etc.; R2 =
 H, Me] as histone deacetylase (HDAC) inhibitors is described. HDAC
 inhibitors have considerable potential as new anti-proliferative agents.

Selected compds. were shown to inhibit both human endothelial cell proliferation, and the formation of tubules (neovascularization) in an in vitro model of angiogenesis.

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Fully automated multi-step solution phase synthesis using polymer supported reagents: preparation of histone deacetylase inhibitors. [Erratum to document cited in CA140:027645]
AN 2003:648659 CAPLUS
DN 141:106239
TI Fully automated multi-step solution phase synthesis using polymer supported reagents: preparation of histone deacetylase inhibitors. [Erratum to document cited in CA140:027645]
AU Vickerstaffe, Emma; Warrington, Brian H.; Ladlow, Mark; Ley, Steven V.
CS GlaxoSmithKline Cambridge Technology Centre, University of Cambridge, Cambridge, CB2 1EW, UK
SO Organic & Biomolecular Chemistry (2003), 1(15), 2807
CODEN: OBCRAK; ISSN: 1477-0520
PB Royal Society of Chemistry
DT Journal
LA English
AB In Reference 6, the principal author Dr. D. Delorme was omitted from the reference

L11 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Fully automated multi-step solution phase synthesis using polymer supported reagents: preparation of histone deacetylase inhibitors
AN 2003:534856 CAPLUS
DN 140:27645
TI Fully automated multi-step solution phase synthesis using polymer supported reagents: preparation of histone deacetylase inhibitors
AU Vickerstaffe, Emma; Warrington, Brian H.; Ladlow, Mark; Ley, Steven V.
CS GlaxoSmithKline Cambridge Technology Centre, University of Cambridge, Cambridge, CB2 1EW, UK
SO Organic & Biomolecular Chemistry (2003), 1(14), 2419-2422
CODEN: OBCRAK; ISSN: 1477-0520
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 140:27645
AB The first fully automated multi-step polymer assisted solution phase (PASP) synthesis is described. An array of histone deacetylase (HDAC) inhibitors, 3- and 4-RSO2NR1C6H4CH:CHCONHOH [R = 4-PhC6H4, 4-MeC6H4, 4-ClC6H4; R1 = H, Me, PhCH2] was prepared by an unattended 4-5 step sequence incorporating in-line catch and release purification

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of hydroxamic acids as inhibitors of histone deacetylase
AN 2001:396861 CAPLUS
DN 135:5455
TI Preparation of hydroxamic acids as inhibitors of histone deacetylase
IN Delorme, Daniel; Ruel, Rejean; Lavoie, Rico; Thibault, Carl; Abou-khalil, Elie
PA Methylgene, Inc., Can.
SO PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001038322	A1	20010531	WO 2000-IB1881	20001122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2391952	A1	20010531	US 1999-167035P	P 19991123
				CA 2000-2391952	20001122
				US 1999-167035P	P 19991123
				WO 2000-IB1881	W 20001122
	EP 1233958	A1	20020828	EP 2000-981535	20001122
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
				US 1999-167035P	P 19991123
				WO 2000-IB1881	W 20001122
	US 6541661	B1	20030401	US 2000-718265	20001122
				US 1999-167035P	P 19991123
	JP 2003514904	T	20030422	JP 2001-540085	20001122
				US 1999-167035P	P 19991123
				WO 2000-IB1881	W 20001122
	AU 783504	B2	20051103	AU 2001-18768	20001122
				US 1999-167035P	P 19991123
				WO 2000-IB1881	W 20001122
	EP 1748046	A2	20070131	EP 2006-11600	20001122
	R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR, AL, LT, LV, MK, RO, SI				
				US 1999-167035P	P 19991123
				EP 2000-981535	A3 20001122
	AU 2006200456	A1	20060302	AU 2006-200456	20060202
				AU 2001-18768	A3 20001122
OS	MARPAT 135:5455				
GI					



AB The title compds. CyLlArYlCONHZ [Cy = (un)substituted cycloalkyl, aryl, heteroaryl, etc.; Ll = (CH₂)_mW (wherein m = 0-4; W = CONH, SO₂NH, NHCO, NHSO₂, NHCONH); Ar = (un)substituted arylene which may be fused to an aryl, heteroaryl, etc.; Yl = a bond, alkylene; Z = aniliny, pyridyl, thiadiazolyl, OM (M = H, a pharmaceutically acceptable cation)], useful for inhibiting histone deacetylase enzymic activity, were prepared E.g., a multi-step synthesis of the title compound I which showed IC₅₀ of 7 μM against histone deacetylase in nuclear exts. from H446 cells (pooled HDACs), was given. The invention also provides compns. and methods for treating cell proliferative diseases and conditions.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of sulfonamidobenzenehydroxamates and analogs as matrix

metalloproteinase and TACE inhibitors
 AN 1999:495123 CAPLUS
 DN 131:129760
 TI Preparation of sulfonamidobenzenehydroxamates and analogs as matrix metalloproteinase and TACE inhibitors
 IN Levin, Jeremy Ian; Du, Mila T.; Venkatesan, Aranapakam Mudumbai; Nelson, Frances Christy; Zask, Arie; Gu, Yansong
 PA American Cyanamid Co., USA
 SO U.S., 68 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5929097	A	19990727	US 1997-944593 US 1996-28504P	19971006 P 19961016

OS MARPAT 131:129760
 AB RSO₂N(CH₂R₇)ZCONHOH [I; R = (un)substituted (hetero)aryl; R₇ = H, alkyl, Ph, etc.; Z = (un)substituted phenylene or -naphthylene] were prepared Thus, 2-(H₂N)C₆H₄CO₂Me was amidated by 4-(MeO)C₆H₄SO₂Cl and the N-benzylated product converted in 2 steps to I [R = C₆H₄(OMe)-4, R₇ = Ph, Z = 1,2-phenylene]. Data for biol. activity of I were given.

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
 TI The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
 AN 1998:251153 CAPLUS
 DN 128:308308
 TI The preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
 IN Levin, Jeremy Ian; Du Mila, T.; Venkatesan, Aranapakam Mudumbai; Nelson, Frances Christy; Zask, Arie; Gu, Yansong
 PA American Cyanamid Company, USA
 SO PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9816503	A2	19980423	WO 1997-US18280	19971008
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2268894	A1	19980423	US 1996-732631 CA 1997-2268894 US 1996-732631 WO 1997-US18280	A 19961016 19971008 A 19961016 W 19971008
	AU 9851458	A	19980511	AU 1998-51458	19971008
	AU 731737	B2	20010405	US 1996-732631 WO 1997-US18280	A 19961016 W 19971008
	EP 938471	A1	19990901	EP 1997-946246	19971008
	EP 938471	B1	20011212		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,				

SI, LT, LV, FI, RO

BR 9712525	A	19991019
CN 1240429	A	20000105
HU 200000641	A2	20001028
JP 2001504809	T	20010410
AT 210637	T	20011215
ES 2166102	T3	20020401
PT 938471	T	20020531
ZA 9709233	A	19990415
TW 410220	B	20001101
KR 2000049196	A	20000725
HK 1021178	A1	20020404

US 1996-732631	A	19961016
WO 1997-US18280	W	19971008
BR 1997-12525		19971008
US 1996-732631	A	19961016
WO 1997-US18280	W	19971008
CN 1997-180613		19971008
US 1996-732631	A	19961016
WO 1997-US18280	W	19971008
HU 2000-641		19971008
US 1996-732631	A	19961016
WO 1997-US18280	W	19971008
JP 1998-518448		19971008
US 1996-732631	A	19961016
WO 1997-US18280	W	19971008
AT 1997-946246		19971008
US 1996-732631	A	19961016
WO 1997-US18280	W	19971008
ES 1997-946246		19971008
US 1996-732631	A	19961016
PT 1997-946246		19971008
US 1996-732631	A	19961016
ZA 1997-9233		19971015
US 1996-732631	A	19961016
TW 1997-86114187		19971015
US 1996-732631	A	19961016
KR 1999-703294		19990415
US 1996-732631	A	19961016
HK 2000-100090		20000106
US 1996-732631	A	19961016
WO 1997-US18280	W	19971008

OS MARPAT 128:308308
GI



II

AB The invention relates to novel, low mol. weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF- α converting enzyme (TACE, tumor necrosis factor- α converting enzyme). The compds. are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation,

keratoconus, Sjogren's syndrome, myopia, ocular tumors, and ocular angiogenesis/neovascularization. The invention compds. are represented by the formula ZSO₂N(CH₂R₇)ACONHOH [I; A = (un)substituted Ph or naphthyl; Z = (un)substituted aryl, heteroaryl, or benzo-fused heteroaryl; R₇ = H, (un)substituted alk(en/yn)yl, Ph, naphthyl, 5- or 6-membered heteroaryl, cycloalkyl, or cycloheteroalkyl; or R₇CH₂NA forms a non-aromatic 1,2-benzo-fused 7- to 10-membered heterocyclic ring with an optional addition benzo fusion; where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A], and include pharmaceutically acceptable salts, optical isomers, and diastereomers. Prepns. of over 400 compds., including I and their intermediates, are given. For instance, 2-[(4-methoxybenzenesulfonyl)amino]-3-methylbenzoic acid Me ester (preparation given) was N-alkylated by 3-picolyl chloride-HCl (83%), followed by hydrolysis of the ester with LiOH in aqueous THF (100%), activation with oxalyl chloride, and hydroxamidation with NH₂OH.HCl (51%), to give title compound II. At 50 mg/kg/day in rats with cartilage implants, II gave 44.6% inhibition of cartilage weight loss, and 51.2% inhibition of cartilage collagen loss.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
24.98	347.99

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.46	-16.38

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:05:52 ON 20 FEB 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623PAZ

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'CAPLUS' AT 12:56:05 ON 20 FEB 2007

FILE 'CAPLUS' ENTERED AT 12:56:05 ON 20 FEB 2007

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
24.98	347.99

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.46	-16.38

CA SUBSCRIBER PRICE

=> d his

(FILE 'HOME' ENTERED AT 10:20:08 ON 20 FEB 2007)

FILE 'REGISTRY' ENTERED AT 10:20:20 ON 20 FEB 2007

L1 STRUCTURE UPLOADED

L2 2 SEARCH L1 EXACT FULL

L3 0 \\D SCAN

FILE 'CAPLUS' ENTERED AT 10:40:19 ON 20 FEB 2007
L4 2 L2

FILE 'REGISTRY' ENTERED AT 11:23:51 ON 20 FEB 2007
L5 STRUCTURE UPLOADED
L6 0 SEARCH L5 SSS SAM
L7 29 SEARCH L5 SSS FULL
SAVE TEMP L7 RAWHITS/A

FILE 'CAPLUS' ENTERED AT 11:26:30 ON 20 FEB 2007
L8 12 L7
SAVE TEMP L8 1STSTABHITS/A ENDS/A
SAVE TEMP L8 ONESTABHITS/A

FILE 'REGISTRY' ENTERED AT 11:57:25 ON 20 FEB 2007
L9 STRUCTURE UPLOADED
L10 5 SEARCH L9 SSS SAM

FILE 'CAPLUS' ENTERED AT 11:59:30 ON 20 FEB 2007
L11 7 L10

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	25.92	348.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.46	-16.38

FILE 'REGISTRY' ENTERED AT 12:57:20 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6
DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.90	349.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00 -16.38

FILE 'STNGUIDE' ENTERED AT 12:58:40 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 16, 2007 (20070216/UP).

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.06	349.89

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-16.38

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 12:58:50 ON 20 FEB 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6
DICTIONARY FILE UPDATES: 19 FEB 2007 HIGHEST RN 921921-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> search 19 sss full

FULL SEARCH INITIATED 12:59:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 100701 TO ITERATE

100.0% PROCESSED 100701 ITERATIONS
SEARCH TIME: 00.00.02

318 ANSWERS

L12 318 SEA SSS FUL L9


=> d scan

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 2-Propenamide, 3-[4-[[[9-ethyl-9H-carbazol-3-yl)amino]sulfonyl]phenyl]-N-
hydroxy-, (2E)- (9CI)

MF C23 H21 N3 O4 S


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):6

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-hydroxy-3-[3-[[4-methoxyphenyl]amino]sulfonyl]phenyl]- (9CI)
 MF C16 H16 N2 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, N-hydroxy-2-[[[4-methoxyphenyl]amino]sulfonyl]- (9CI)
 MF C14 H14 N2 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, 4-[[[4-[(hydroxyamino)carbonyl]phenyl]amino]sulfonyl]-N,N-dimethyl- (9CI)
 MF C16 H17 N3 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-hydroxy-3-[4-[(2-naphthalenylamino)sulfonyl]phenyl]-
 (9CI)
 MF C19 H16 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-hydroxy-3-[4-[[4-(4-nitrophenyl)sulfonyl]amino]phenyl]-
 (9CI)
 MF C15 H13 N3 O6 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, 4-[[[2-(diethylamino)-6-quinolinyl]sulfonyl]amino]-N-hydroxy-,
 mono(trifluoroacetate) (salt) (9CI)
 MF C20 H22 N4 O4 S . C2 H F3 O2

CM 1




CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):20


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-hydroxy-3-[3-[(2-thienylsulfonyl)amino]phenyl]-, (2E)-
 (9CI)
 MF C13 H12 N2 O4 S2

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, N-hydroxy-3-[4-[(4-methylphenyl)amino]sulfonyl]phenyl]-
 (9CI)
 MF C16 H16 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benamide, 4-[[[2-[(3,4-difluorophenyl)methyl]-6-
 benzoxazolyl]sulfonyl]amino]-N-hydroxy- (9CI)
 MF C21 H15 F2 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, 3-[3-[[[3,5-bis(trifluoromethyl)phenyl]amino]sulfonyl]phenyl]-N-hydroxy-, (2E)- (9CI)
 MF C17 H12 F6 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, 3,3-bis[3-[[[4-bromophenyl]sulfonyl]amino]phenyl]-N-hydroxy- (9CI)
 MF C27 H21 Br2 N3 O6 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Heptene-4,6-diynamide, N-hydroxy-7-[3-[(phenylsulfonyl)amino]phenyl]-,
 (E)- (9CI)
 MF C19 H14 N2 O4 S

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, 4-[[[4-(dimethylamino)phenyl]sulfonyl]amino]-N-hydroxy- (9CI)
 MF C15 H17 N3 O4 S
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, 3-[3-[[[4-(difluoromethoxy)phenyl]amino]sulfonyl]phenyl]-N-hydroxy- (9CI)
 MF C16 H14 F2 N2 O5 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benamide, 4-[(benzo[b]thien-2-ylsulfonyl)amino]-N-hydroxy- (9CI)
MF C15 H12 N2 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benamide, 4-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]-N-hydroxy- (9CI)
MF C12 H13 N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-hydroxy-3-[4-[[(4-methoxyphenyl)sulfonyl]amino]phenyl]-, (2E)- (9CI)
MF C16 H16 N2 O5 S

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, 3-[4-[(2-dibenzofuranylsulfonyl)amino]phenyl]-N-hydroxy-
 (9CI)
 MF C21 H16 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 3-Thiophenecarboxylic acid, 5-[[[4-[(hydroxyamino)carbonyl]phenyl]amino]sulfonyl]-4-methoxy-, methyl ester (9CI)
 MF C14 H14 N2 O7 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 2-Propenamide, 3-[3-[[[4-bromophenyl]amino]sulfonyl]phenyl]-N-hydroxy-,
 (2E)- (9CI)

MF C15 H13 Br N2 O4 S


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-hydroxy-3-phenyl-3-[[4-(trifluoromethyl)phenyl]sulfonyl]amino]phenyl]-, (2Z)- (9CI)
MF C22 H17 F3 N2 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-[[5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-N-hydroxy- (9CI)
MF C16 H13 Cl N2 O4 S2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-hydroxy-3-[2-[(2-naphthalenylamino)sulfonyl]phenyl]-,

(2E)- (9CI)
MF C19 H16 N2 O4 S


Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Propenamide, N-hydroxy-3-[[2-[[4-methoxyphenyl]sulfonyl]amino]-5-nitrophenyl]-3-phenyl-, (2E)- (9CI)
MF C22 H19 N3 O7 S

Double bond geometry as shown.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 2-Naphthaleneheptanamide, N-hydroxy-1-[[[4-methylphenyl]sulfonyl]amino]- (9CI)
MF C24 H28 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L12 318 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, N-hydroxy-4-[[[4-(1-methylethyl)phenyl]sulfonyl]amino]- (9CI)
 MF C16 H18 N2 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> save temp l12 rawsulphamde/a
 ANSWER SET L12 HAS BEEN SAVED AS 'RAWSULPHAMDE/A'

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
173.00	522.89

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-16.38

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 13:00:49 ON 20 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Feb 2007 VOL 146 ISS 9
FILE LAST UPDATED: 19 Feb 2007 (20070219/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> l12

L13 131 L12

=> file save temp l13 sulphnmderefs/a

'SAVE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> save temp l13 sulphnmderefs/a

SULPHNMDEREFS/A IS NOT A VALID SAVED NAME

Enter the name you wish to use for the saved query, answer set, or L-number list. The name must:

1. Begin with a letter,
2. Have 1-12 characters,
3. Contain only letters (A-Z) and numbers (0-9),
4. End with /Q for a query (search profile, structure, or screen set), /A for an answer set, or /L for an L-number list.
5. Not already be in use as a saved name,
6. Not be END, SAV, SAVE, SAVED
7. Not have the form of an L-number (Lnnn).

ENTER NAME OR (END):end

=> save temp l13 sulphrefs/a

ANSWER SET L13 HAS BEEN SAVED AS 'SULPHREFS/A'

=> d l13 125-131 ti

L13 ANSWER 125 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Silver halide photographic material containing hydrazine compound

L13 ANSWER 126 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of aromatic hydroxamic acid compounds for preventing and treating neurodegenerative diseases

L13 ANSWER 127 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD

L13 ANSWER 128 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI (2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic Acid and Its Derivatives as Novel and Potent Inhibitors of ras Transformation

L13 ANSWER 129 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors

L13 ANSWER 130 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Synthesis and screening of some new methyl salicylate-5-sulfonamides containing active units as analgesic agents

L13 ANSWER 131 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI o-Hydroxybenzohydroxamic acids

=> d 113 126-131 ti fbib abs

L13 ANSWER 126 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of aromatic hydroxamic acid compounds for preventing and treating neurodegenerative diseases

AN 1996:733885 CAPLUS

DN 126:7829

TI Preparation of aromatic hydroxamic acid compounds for preventing and treating neurodegenerative diseases

IN Kato, Kaneyoshi; Miki, Shokyo; Naruo, Ken-Ichi; Takahashi, Hideki

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 83 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 737671	A2	19961016	EP 1996-302494	19960410
	EP 737671	A3	19970502		
	EP 737671	B1	20011212		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				JP 1995-84342	A 19950410
				JP 1995-215932	A 19950824
JP 09118660	A	19970506		JP 1996-86160	19960409
				JP 1995-84342	A 19950410
				JP 1995-215932	A 19950824
US 5804601	A	19980908		US 1996-629623	19960409
				JP 1995-84342	A 19950410
				JP 1995-215932	A 19950824
CA 2173806	A1	19961011		CA 1996-2173806	19960410
				JP 1995-84342	A 19950410
				JP 1995-215932	A 19950824
HU 9600924	A2	19970128		HU 1996-924	19960410
				JP 1995-84342	A 19950410
				JP 1995-215932	A 19950824
AT 210635	T	20011215		AT 1996-302494	19960410
				JP 1995-84342	A 19950410
				JP 1995-215932	A 19950824

OS MARPAT 126:7829

AB The title compds. ArR1CHCH2QCONHOR2 (I) and ArR1C:CHQCONHOR2 [II; R1 = H, cyano, an optionally substituted hydrocarbon or Ph or naphthyl, NR3R4, acyl; R2 = acyl; R3, R4 = H, acyl, optionally substituted hydrocarbon group, or R3 and R4 may combine together with the adjacent N atom to form a ring; Ar = (un)substituted C6-14 aryl or 5-11 membered heteroaryl; Q = divalent C2-8 aliphatic hydrocarbon group] or salts thereof are prepared I and II (R2 = H, acyl) having excellent anti-neurodegenerative activity with a low cytotoxicity are useful for preventing or treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Down's syndrome, Pick's disease, multiple sclerosis, and diseases typically mediated by viral infections, etc. Thus, 6-(4-methoxyphenyl)-6-(3-methyl-1,4-naphthoquinon-2-yl)hexanohydroxamic acid was reacted with Ac2O in the

presence of pyridine to give I (R1 = 3-methyl-1,4-naphthoquinon-2-yl, Ar = 4-MePh, Q = (CH₂)₃, R2 = Ac). I (R1 = 3-methyl-1,4-naphthoquinon-2-yl, Ar = 4-MeOPh, Q = (CH₂)₃, R2 = H) showed IC₅₀ of 0.08 μ M against lipopolysaccharides-induced NO production in a mixed rat cerebral cell culture system.

L13 ANSWER 127 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD

AN 1996:463426 CAPLUS

DN 125:157903

TI Oxamflatin: a novel compound which reverses malignant phenotype to normal one via induction of JunD

AU Sunoda, Hikaru; Nishida, Kazuyo; Takayuki, Nishida; Yoshioka, Takayuki; Ohtani, Mitsuaki; Sugita, Kenji

CS Shionogi Res. Lab., Shionogi & Co., Ltd., Osaka, 553, Japan

SO Oncogene (1996), 13(1), 143-149

CODEN: ONCNE5; ISSN: 0950-9232

PB Stockton

DT Journal

LA English

AB In the course of screening for inhibitors of tumorigenic phenotype of K-ras-transformed NIH3T3 cells (DT cells), we found a novel compound, oxamflatin, an aromatic sulfonamide hydroxamate derivative, which induces flat phenotype in these cells and suppresses their anchorage-independent growth. In contrast to dT cells, in v-raf-transformed NIH3T3 cells, no change in their morphol. and no specific inhibition of their anchorage-independent growth was observed. Interestingly, oxamflatin was effective to NIH3T3 cells transformed by constitutively activated mutant of MEK, indicating the possibility that oncogene-induced morphol. change is not necessarily induced by common signaling pathway such as MAP kinase cascade. In oxamflatin-treated DT cells, the expression of transcription factor junD was highly augmented, resulting in trans-activation of fibronectin gene by junD via cAMP responsive element in its promoter. This behavior of junD was confirmed to correlate well with partial blocking of malignant phenotype in DT cells. Thus, oxamflatin can be categorized as the first reagent which induces genes whose products can interfere with oncogene-dependent transformation.

L13 ANSWER 128 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI (2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic Acid and Its Derivatives as Novel and Potent Inhibitors of ras Transformation

AN 1996:382877 CAPLUS

DN 125:75336

TI (2E)-5-[3-[(Phenylsulfonyl)amino]phenyl]-pent-2-en-4-ynohydroxamic Acid and Its Derivatives as Novel and Potent Inhibitors of ras Transformation

AU Ohtani, Mitsuaki; Matsuura, Takaharu; Shirahase, Kazuhiro; Sugita, Kenji

CS Shionogi Research Laboratories, Shionogi Co., Osaka, 553, Japan

SO Journal of Medicinal Chemistry (1996), 39(15), 2871-2873

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English



OS CASREACT 125:75336

AB In the course of screening compds. exhibiting reversion of the cell morphol. transformed by ras-oncogene, the authors found a novel type of aromatic hydroxamic acid derivs. Structure-activity relation (SAR) study was tried and (2E)-5-[3-(phenylsulfonylamino)phenyl]pent-2-en-4-ynohydroxamic acid was found to show very potent activity with an MIC value of 0.04 μ M. It reversed the phenotype of ras-transformed cells to the normal one, indicating reversion of tumor characteristic to normal one. This is the first report describing the synthesis of novel aromatic conjugated hydroxamic acid derivs. inducing genes with products that can interfere

with the ras-dependent transformation.

L13 ANSWER 129 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors
 AN 1994:54333 CAPLUS
 DN 120:54333
 TI Preparation of sulfonamidoaryl hydroxamic acids as inflammation and tumor inhibitors
 IN Ohtani, Mitsuaki; Arita, Hitoshi; Sugita, Kenji; Matsuura, Takaharu; Shirahase, Kazuhiro
 PA Shionogi and Co., Ltd., Japan
 SO PCT Int. Appl., 125 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9312075	A1	19930624	WO 1992-JP1593	19921207
	W: JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 570594	A1	19931124	JP 1991-350793	A 19911210
	EP 570594	B1	19970730	EP 1992-924883	19921207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
				JP 1991-350793	A 19911210
				WO 1992-JP1593	W 19921207
	AT 156116	T	19970815	AT 1992-924883	19921207
				JP 1991-350793	A 19911210
	ES 2107557	T3	19971201	ES 1992-924883	19921207
				JP 1991-350793	A 19911210
	JP 3342485	B2	20021111	JP 1993-510775	19921207
				JP 1991-350793	A 19911210
				WO 1992-JP1593	W 19921207
	US 5534654	A	19960709	US 1993-98272	19930803
				JP 1991-350793	A 19911210
				WO 1992-JP1593	W 19921207
OS	CASREACT 120:54333; MARPAT 120:54333				
GI					



AB The title compds. R2ONR1COXALYNR3BA2 (I) [A1 = (substituted) aromatic ring, aromatic heterocyclic ring; A2 = H, (substituted) aryl, aromatic heterocyclic ring; B = single bond, B1B2; B1 = CO, SO2; B2 = alkylene, alkenylene, etc.; X = (substituted) alkylene which may have O, S, N and may have unsatd. bond; Y = single bond, heteroatom, (substituted) alkylene which may contain heteroatom and may have unsatd. bond; X and N (which is linked to Y) may together form a moiety Q; R1 - R3 = H, (substituted) alkyl,

aryl] were prepared I inhibit hemangioendothelial cell growth, the development of a lymphocyte adhesion factor, and ras gene-induced cell transformation and are useful as inflammation and tumor inhibitors. Condensation of carboxylic acid (E)-II (R = OH) with NH₂OH.HCl in DMF containing N-hydroxysuccinimide, N,N-dicyclohexylcarbodiimide, and Et₃N gave (E)-II (R = NHOH). Hydroxamic acid (E)-III in vitro exhibited MIC of 0.039 µM against ras gene-induced cell transformation.

L13 ANSWER 130 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Synthesis and screening of some new methyl salicylate-5-sulfonamides containing active units as analgesic agents
 AN 1989:614401 CAPLUS
 DN 111:214401
 TI Synthesis and screening of some new methyl salicylate-5-sulfonamides containing active units as analgesic agents
 AU Hannout, I. B.; Sharief, A. M. Sh.; Ammar, Y. A.; Mohamed, Y. A.; Youssef, A. A.
 CS Fac. Sci., Al-Azhar Univ., Cairo, Egypt
 SO Journal of the Serbian Chemical Society (1988), 53(7), 353-61
 CODEN: JSCSEN; ISSN: 0352-5139
 DT Journal
 LA English
 OS CASREACT 111:214401
 GI



AB Treatment of ClSO₂C₆H₃(CO₂Me)OH-3,4 with amines under various conditions afforded sulfonamides, e.g. I (R = alkyl, aryl) or amidosulfonylsalicylamides, e.g. II (R₁ = H, R₂ = cyclohexyl, 4-AcC₆H₄). Seven products were screened for toxicity and exhibited mild or weak analgesic activity.

L13 ANSWER 131 OF 131 CAPLUS COPYRIGHT 2007 ACS on STN

TI o-Hydroxybenzohydroxamic acids

AN 1958:56242 CAPLUS

DN 52:56242

OREF 52:10184a-d

TI o-Hydroxybenzohydroxamic acids

IN Priewe, Hans; Rutkowski, Rudi

PA Schering A.-G.

DT Patent

LA Unavailable

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 855866		19521117	DE	

AB o-Hydroxybenzohydroxamic acids are obtained by the reaction of p-substituted o-hydroxybenzoic esters with NH₂OH in alkaline solns. with subsequent isolation of the free acids. Examples: 167 g. Me 4-amino-2-hydroxybenzoate and 90.4 g. NH₂OH.HCl (I) in 2 l. 2N NaOH left to stand for several hrs. and treated with HCl gives 4-amino-2-hydroxybenzohydroxamic acid-HCl. Treatment with bicarbonate solution gives 106 g. free acid, needles, m. 187° (decomposition). Me

4-nitro-2-hydroxybenzoate (1 mole) with 1.3 moles I gives 65% 4-nitro-2-hydroxybenzohydroxamic acid, light yellow needles, m. 214°; Me 4-acetamido-2-hydroxybenzoate (1 mole) with 1.3 moles I gives 64.5% 4-acetamido-2-hydroxybenzohydroxamic acid, m. 218°; Me N-carbethoxy-4-amino-2-hydroxybenzoate (f.p. 145°, 8 g.) with 7 g. I gives 49.6% N-carbethoxy-4-amino-2-hydroxybenzohydroxamic acid, m. 178-9°; Me 3,5-dibromo-4-amino-2-hydroxybenzoate (m. 138-40°) with I gives 3,5-dibromo-4-amino-2-hydroxybenzohydroxamic acid, m. 194-5°; Me 4-iodosalicylate (1.2 g.) with 0.4 g. I gives 57% 4-iodo-2-hydroxybenzohydroxamic acid, m. 202° (decomposition); Me 4-benzenesulfonamido-2-hydroxybenzoate (2.3 g., m. 189-90°) with 0.7 g. I gives 59% 4-benzenesulfonamido-2-hydroxybenzohydroxamic acid, m. 222° (decomposition).

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
23.59	546.48

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.68	-21.06

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:06:01 ON 20 FEB 2007